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Chapter I: General introduction 
 
I.1 Phosphatase of regenerating liver 3 (PRL-3) 
I.1.1. Protein phosphorylation/dephosphorylation 
Eukaryotic cells are able to coordinate rapid responses to external stimuli as well as to 
preserve internal homeostasis. The final cellular outcome is the result of an integrated 
network of fine-tuned intracellular signalling pathways that are mainly based on 
dynamic events of phosphorylation and dephosphorylation. These modifications can 
for example activate or inhibit protein enzymatic activity, change protein-protein 
interaction affinity and/or modify protein subcellular localization. Protein 
phosphorylation is a reversible posttranslational modification that occurs mainly on 
hydroxyl-containing residues: serine, threonine and tyrosine. Protein kinases are the 
enzymes that catalyze the covalent attachment of a phosphoryl group to a hydroxyl-
containing side chain, whereas protein phosphatases catalyze the transfer of the 
phosphate from a phosphoprotein to a water molecule (Cohen, 2002). Notably, 
kinases and phosphatases are also involved in the regulation of signal transduction 
affecting the phosphorylation of non-protein substrates, such as inositol phospholipids 
(Majerus and York, 2009).  
Protein phosphatases have been classified into mechanistically distinct 
superfamilies that do not share any structural similarities and apparently evolved 
independently (Alonso et al., 2004). Based on the mechanism of catalysis protein 
phosphatases can be classified in: 
a) The serine/threonine phosphatases superfamily wherein the catalysis proceeds                 
without a phosphoenzyme intermediate, with the direct hydrolysis of the 
phosphosubstrate; the process strictly requires the presence of metal ions in the 
enzyme active site. The substrate specificity of this superfamily is obtained by 
combinatorial interaction between catalytic and regulatory subunits rather than 
specific aminoacid sequence recognition (Brautigan, 2013). 
b) The haloacid dehalogenase (HAD) superfamily in which the nucleophile aspartic 
acid in the active site is an absolute requirement for the activity (Seifried et al., 
2013).  
c) The protein tyrosin phosphatase (PTP) superfamily wherein the catalytic cysteine 
in the active site forms a phosphoenzyme intermediate in the reaction with the 
substrate. The PTP superfamily is the largest class with 96 catalytically active 
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members and all the members share the consensus catalytic signature motif His-
Cys-X5-Arg (X= any aminoacid) (Li et al., 2013; Tonks, 2006, 2013). The PTP 
superfamily will be discussed in detail in the following paragraphs. 
  
I.1.2. Protein Tyrosin phosphatases (PTPs) 
I.1.2.A. Mechanism of catalysis 
In the PTP superfamily the dephosphorylation reaction proceeds with a two-step 
mechanism (Fig. I.1). The first step involves the nucleophilic attack of the phosphate 
group by the thiol group of the catalytic cysteine. This reaction is facilitated by the 
presence of a conserved aspartic acid from a flanking loop that functions as a general 
acid, protonating the leaving group of the substrate. In the second step the same 
aspartic acid residue acts as a general base activating a water molecule leading to the 
hydrolysis of the phosphocysteine intermediate. This second step, in almost all PTPs, 
is facilitated by the presence of a serine or threonine residue that follows the arginine 
in the His-Cys-X5-Arg signature. The hydroxyl group of this conserved residue is 
important for the breakdown of the phosphoenzyme intermediate (Kolmodin and 
Aqvist, 2001).  
 
 
Figure I.1. PTPs catalytic mechanism. A detailed description of the PTPs catalytic 
mechanism is reported in the main text. Black boxes highlight the critical catalytic 
residues. Adapted from Tonks (2006).  
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I.1.2.B. PTP classification 
Among the PTP superfamily two classes can be defined: the classical PTPs and the 
dual specificity phosphatases (DSPs) (Alonso et al., 2004; Tonks, 2006).  
a) The classical PTP family comprises transmembrane as well as cytoplasmic 
enzymes characterized by phosphotyrosine (pTyr) specificity (Tonks, 2006). One 
of the best-characterized classical PTP is PTP1B. PTP1B is considered a 
prototype of this family, given that most of the findings on its structure, regulation 
and function have revealed principles valid for the whole classical PTP family 
(Tonks, 2003). 
b) The DSPs family is a heterogeneous group of non-transmembrane phosphatases 
characterized by a shallow conformation of the catalytic pocket that allows them 
to accommodate a broad range of substrates. DSPs can dephosphorylate 
phosphoserine (pSer)/phosphothreonine (pThr) and pTyr residues as well as non-
protein substrates. Some members of DSPs family, for example, show activity 
against phosphoinositides (Patterson et al., 2009; Pulido et al., 2013; Tonks, 
2013). The most striking example of DSPs with a broad range of substrate 
specificity is the phosphatase PTEN (phosphatase and tensin homolog). The 
PTEN catalytic pocket is sufficiently large to accommodate the head group of 
phosphoinositides (PtdIns) as well as tyrosine-, threonine- and serine-
phosphorylated phosphopepetides, with an unusual preference for highly acidic 
sequences (Song et al., 2012). In vivo experiments have confirmed PTEN activity 
against the phosphate in the 3’ position of the inositol ring of PtdIns, mainly 
PtdIns(3,4,5)P3 (see chapter I.2 for a detailed description of phosphoinositide 
molecules) (Maehama, 1998). Moreover, recently in vivo evidence of the protein 
phosphatase activity of PTEN has been provided, showing that the enzyme is able 
to dephosphorylate itself on the regulatory residues pSer and pThr (Tamguney and 
Stokoe, 2007; Zhang et al., 2012). 
 
I.1.3. Phosphatases of regenerating liver (PRLs) 
PRL phosphatases constitute a class of small (20 kDa), single domain phosphatases 
that belong to the DSP family. There are three members (PRL-1, PRL-2 and PRL-3) 
that share high sequence identity and key structural features unique to this family 
(Fig. I.2). PRLs contain the conserved catalytic PTP signature (His-Cys-X5-Arg) but 
the active site is unusually hydrophobic and instead of the serine/threonine residue 
 4 
that facilitates the breakdown of the phosphoenzyme intermediate an alanine is found 
in that position (Fig. I.1, Fig. I.2) (Al-Aidaroos and Zeng, 2010; Bessette et al., 2008; 
Rios et al., 2013; Stephens et al., 2005). All the three members contain a CAAX 
prenylation motif at the C-terminus (Where C is a cystein, A is an aliphatic 
aminoacid, and X is any aminoacid) that is uniquely characteristic to PRLs. The 
prenylation is essential for the anchoring of proteins to membrane compartments 
(Zeng et al., 2000). In close proximity to the farnesylation site, a stretch of basic 
aminoacids (polybasic sequence) facilitates the binding to the plasma membrane by 
interaction with negatively charged membrane phospholipids (Sun et al., 2007). 
Structural studies on PRL-1 and PRL-3 have also suggested a potential mechanism 
for in vivo regulation of PRL’s activity based on the formation of an intramolecular 
disulfide bond between the catalytic cystein (Cys104) and the conserved cystein in 
position 49 (Fig. I.2) (Skinner et al., 2009). Notably, redox-regulation of the catalytic 
activity is not a PRL unique characteristic but has also been described for other DSP, 
such as PTEN (Boivin and Tonks, 2010). 
 
 
Figure I.2. PRLs sequence alignment. Sequence alignment of human PRL-1, PRL-2 
and PRL-3. Red box: cysteine involved in the redox-regulation of the catalytic activity 
(Cys 49 in PRL-3). Purple box: Aspartic acid involved in the mechanism of catalysis 
(Asp 72 in PRL-3). Black box: PTP signature motif, catalytic cysteine in bold (Cys 
104 in PRL-3). The natural substitution Ser/Thr to Alanine is highlighted in red bold 
(Ala 111 in PRL-3). Orange box: Golgi targeting MXXE motif. Blue box: stretch of 
positive charge residues (polybasic sequence). Green box: CAAX prenylation motif. 
Adapted from B.J. Stephens (2005). 
 
Beyond sequence and structural similarities, PRLs share also the ability to promote 
cell proliferation, migration, invasion, tumor growth and metastasis (Al-Aidaroos and 
Zeng, 2010; Bessette et al., 2008; Stephens et al., 2005). Multiple lines of evidence 
are reinforcing the opinion that PRLs are a unique class of oncogenic phosphatases 
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that play a causative role in tumor metastasis (Guzińska-Ustymowicz and Pryczynicz, 
2011) (see paragraph I.C.5. for a detailed description of PRL-3 in cancer metastasis). 
Despite their similarities, PRLs exhibit a distinct pattern of tissue distribution. PRL-
1 and PRL-2 are ubiquitously expressed in adult human tissues, although considerable 
variation in PRL-1 levels has been observed among different tissue types (Dumaual et 
al., 2006). In contrast, the expression of PRL-3 seems to be much more restricted. 
PRL-3 mRNA is largely confined to heart and skeletal muscle although, at the protein 
level, the expression was confirmed in rat fetal heart but neither in rat nor in human 
adult heart (Guo et al., 2006; Matter et al., 2001).  
This thesis will mainly focus on PRL-3 and the next paragraphs will provide an 
overview on the current status of PRL-3 research.  
 
I.1.3.A.The subcellular localization of PRL-3 
The subcellular localization of PRL-3 is mainly governed by its C-terminal lipidation. 
It has been shown recently that the protein is subjected to a dual lipidation, i.e. 
farnesylation on the first and palmitoylation on the second cysteine of the CAAX box 
(Fig. I.2). The protein is mainly associated with the plasma membrane and 
intracellular punctuate structures that are suggested to be early endosomes (Nishimura 
and Linder, 2013; Zeng et al., 2000). Recently, it has also been reported that PRL-3 
can associate with the Golgi apparatus and with the perinuclear endosomal 
compartments (Krndija et al., 2012). When the lipidation process is impaired, for 
example by application of prenylation inhibitors, the protein relocalizes to the 
nucleus; most probably the C-terminal polybasic sequence also acts as a nuclear 
localization signal. However a biological function of PRL-3 in the nucleus has not yet 
been demonstrated (Zeng et al., 2000). 
 
I.1.3.B. The regulation of PRL-3 
Multiple and sometimes contradictory scenarios for PRL-3 transcriptional, 
translational and post-translational regulation have been reported. These data are also 
often difficult to integrate considering the different experimental conditions and cell 
lines used. On the other hand, these findings, together with the extremely restricted 
pattern of expression, underline the idea of a fine-tuned regulation of PRL-3 levels 
and most likely activity, typical of oncogenes. Selected examples of PRL-3 regulation 
will be briefly discussed in the next paragraphs. 
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I.1.3.B.1. Transcriptional regulation 
PRL-3 transcription is up-regulated in human umbilical vein endothelial cells 
(HUVEC) after stimulation with the growth factor VEGF (vascular endothelial 
growth factor) through the transcription factor MEF2C (myocyte enhancer factor 2C) 
(Xu et al., 2011). Additionally, it seems that PRL-3 itself, in lung cancer cell lines, is 
able to up-regulate VEGF expression, opening the possibility of a positive feedback 
loop of transcriptional regulation (Ming et al., 2009). Moreover, it has been reported 
that PRL-3 is a direct transcriptional p53 target gene, but contrary results have been 
obtained in different cell lines, suggesting a complex scenario of transcriptional 
regulation that is cell-type specific (Basak et al., 2008; Min et al., 2010). Recently, 
Jiang et al. (2011) reported the first example of PRL-3 negative transcriptional 
regulation. The authors demonstrate that TGFβ (transforming growth factor beta) 
signaling antagonizes PRL-3 expression via Smad3-dependent inhibition of PRL-3 
promoter activity (Jiang et al., 2011). Interestingly, the authors propose that in tumors, 
for example from colorectal cancer, where the TGFβ signaling is often affected, the 
loss of the mentioned inhibitory effect could explain the elevated levels of PRL-3 (see 
below for a detailed description of the role of PRL-3 in cancer metastasis). 
 
I.1.3.B.2. Post-transcriptional regulation 
It has been shown that PRL-3 mRNA and protein levels often do not correlate. This is 
thought to be due to an inhibitory effect of the RNA binding protein PCBP1 (PolyC-
RNA-binding protein 1) on PRL-3 mRNA translation. PCBP1 binds the the 5' 
untranslated region (UTR) of the PRL-3 transcript and suppresses its incorporation 
into the polyribosome (Wang et al., 2010).  
 
I.1.3.B.3. Post-translational regulation 
PRL-3 protein stability is also regulated. In MCF7 cancer cell lines for example, it has 
been shown that PRL-3 is targeted for degradation through the proteasome pathway 
as a result of the interaction with the protein FKBP38 (FK506-binding protein 38) 
(Choi et al., 2011). 
Recently, it has also been reported that PRL-3 can be phosphorylated in vitro and in 
vivo by the tyrosin kinase Src. The primary site of phosphorylation is the conserved 
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Tyr53. The authors also provided a direct link between Tyr 53 phosphorylation on 
PRL-3 and the pro-invasion phenotype associated with PRL-3 overexpression (see 
paragraph I.1.3.d) (Fiordalisi et al., 2013). However, it is not clear by what 
mechanism phosphorylation affects the function of PRL-3 and in particular if the 
phosphorylation regulates the protein’s catalytic activity.  
   
I.1.3.C. Physiological roles of PRL-3  
PRL-3 physiological functions are poorly investigated and unclear at the present. The 
generation of a knockout mouse has not provided clear insight about PRL-3’s 
physiological roles. Mice without functional PRL-3 developed normally and did not 
present any apparent phenotype in the adult life. The only exception was a slight 
perturbation of the sex ratio, with lower number of male mice born (Zimmerman et 
al., 2013). These results are in contrast with the strong phenotype reported in mice 
lacking PRL-2, where reduced placenta development leads to severe fetal growth 
retardation (Dong et al., 2012). Notably, these remarkable differences between PRL-
2/PRL-3 knockout mice may suggest that the functions of the two phosphatases are 
not overlapping in vivo. 
 
I.1.3.D. PRL-3 and cancer metastasis 
PRL-3 was originally identified as a protein that is highly overexpressed in all 
metastatic lesions derived from colorectal cancer (liver, lung, brain, and ovary). 
Notably, in this initial study the protein was neither detected in normal colorectal 
epithelium nor in the primary tumor, introducing the concept of a metastasis-
associated phosphatase (Saha et al., 2001). In the past decade numerous studies have 
shown a tight correlation between elevated PRL-3 expression and the metastatic 
potential and poor prognosis outcome of multiple epithelial cancers, including gastric, 
breast, ovarian and lung cancers (Fig. I.3) (Al-Aidaroos and Zeng, 2010; Bessette et 
al., 2008; Guzińska-Ustymowicz and Pryczynicz, 2011; Rios et al., 2013; Stephens et 
al., 2005). Although it is generally accepted that PRL-3 could be an emerging 
prognostic marker for cancer metastasis, studies on PRL-3 knockout mice have 
recently opened the possibility that PRL-3 could also play a role in primary tumor 
formation. Indeed, PRL-3 knockout mice show a 50% reduction in colon tumors 
development after exposure to procarcinogenic and inflammatory agents (Zimmerman 
et al., 2013).  
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Nude mice-based experiments have extensively validated the causative role of PRL-
3 in cancer metastasis showing that:  
• PRL-3 expression promotes metastatic tumor spreading. Thus, in vivo injection of 
PRL-3-expressing B16 cells (mouse melanoma cells) into mice tail vein resulted 
in metastatic lung and liver lesions (Wu et al., 2004). Similar results were 
independently obtained by Zeng and colleagues, by showing that 100% of mice 
injected with PRL-3-expressing CHO cells (Chinese hamster ovary cells) had 
widespread lung tumors and, in some cases, liver metastasis (Zeng et al., 2003). 
• PRL-3 expression triggers tumor angiogenesis. PRL-3-expressing CHO cells 
injected in nude mice not only promote the development of local tumors but also 
recruit host endothelial cells into the tumors to establish microvasculature (Zeng 
et al., 2003). As discussed previously, PRL-3 expression up-regulated VEGF 
levels in lung cancer cell lines. VEGF is a highly specific mitogen for endothelial 
cells, promoting the growth of blood vessels from pre-existing vasculature; thus it 
has been proposed that PRL-3 could facilitate angiogenesis by promoting VEGF 
expression. Moreover, a direct link between PRL-3 expression and microvessel 
density has been reported in human hepatocellular carcinoma (Zhao et al., 2008). 
Cancer cell lines-based experiments further corroborated the data previously 
discussed. A tight correlation between elevated PRL-3 levels and the acquisition of a 
migratory and invasive cell phenotype has been reported in CHO and B16 cells stably 
expressing ectopic PRL-3. Furthermore, PRL-3 overexpression is also associated with 
a morphological transformation of B16 cells from epithelial-like shape to fibroblast-
like shape. Interestingly, the overexpression of a catalytically inactive mutant (PRL-3 
C104S) has never been associated with any of the mentioned phenotypes (Wu et al., 
2004; Zeng et al., 2003). RNA interfering experiments conducted in cancer cell lines 
that endogenously express high PRL-3 levels support the aforementioned data. For 
example, downregulation of PRL-3 in human colon cancer DLD-1 cells strongly 
reduce their motility and hepatic colonization (Kato et al., 2004). Similar results were 
obtained by reducing the expression of PRL-3 in the highly metastatic melanoma cell 
line B16-BL6 (Qian et al., 2007). Taken together, these data emphasize the role of 
PRL-3 as major player in tumorigenic and metastatic processes. 
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Figure I.3. Timeline of major discoveries in PRL-3 cancer biology. During the last 
decade PRL-3 has been found as a protein highly overexpressed in multiple cancer 
types. The red box highlight the first study, published in 2001, about the role of PRL-3 
in colorectal cancer metastasis. Adapted from Al-Aidaroos and Zeng (2010). 
 
I.1.3.E. Signaling pathways affected by PRL-3 
The aberrant expression of PRL-3 has been connected with the alteration of 
intracellular signal transduction pathways related to cell survival, motility and 
invasion. A brief overview of the main pathways affected by PRL-3 overexpression is 
provided below. 
 
I.1.3.E.1. PRL-3 regulates Rho GTPases 
The small GTPases of the Rho family act as molecular switches, cycling between an 
active (GTP-bound) and an inactive (GDP-bound) conformation. GTP binding 
facilitates their interaction with many effectors molecules and in turn controls 
downstream signaling pathways. The best-characterized mammalian Rho GTPases 
involved in actin cytoskeleton dynamics are Rho (A, B, C isoforms), Rac and Cdc42 
(Ridley, 2012; Sit and Manser, 2011). In colorectal cancer SW480 cells, 
overexpression of PRL-3 increases the fraction of GTP-bound Rho A and C, reduces 
the activity of Rac and has no effect on Cdc42 (Fiordalisi et al., 2006). On the other 
hand, studies conducted in CHO and DLD-1 reported contradictory results, showing 
that not only Rac but also RhoA is inhibited by PRL-3 overexpression (Wang et al., 
2007). Although the authors propose that PRL-3- enhanced cell motility can be 
explained by its effect on Rho GTPase activity, at the moment there are still numerous 
open questions about how, at the molecular level, this happens.  
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I.1.3.E.2. PRL-3 regulates Arf GTPases 
ADP-ribosylation factor (Arf) proteins are an additional family of small GTPases 
involved in actin cytoskeleton remodeling and vesicle trafficking. It has been reported 
that PRL-3 interacts with Arf1, a GTPase classically associated with the Golgi 
apparatus. Specifically, PRL-3 interacts with the active, GTP-boundArf1 and, 
promotes its activation. The interaction is mediated by the Golgi targeting MXXE 
motif (Fig. I.2) and seems to be necessary for the pro-migratory phenotype. The 
authors also propose that PRL-3 enhances cell motility in an Arf1-dependent manner 
by accelerating the recycling of the matrix receptor integrin alpha 5; however, the 
precise mechanism of Arf1 activation by PRL-3 is still missing (Krndija et al., 2012). 
 
I.1.3.E.3. PRL-3 activates Src and PI3K, and promotes epithelial-mesenchymal 
transition (EMT) 
PRL-3 overexpression triggers the activation of two classical oncogenes: the non-
receptor protein tyrosine kinase Src and the phosphoinositide-3-kinase PI3K (Liang et 
al., 2007; Wang et al., 2007). Src activity is involved in a variety of cellular processes 
such as differentiation, motility and adhesion. It is well established that the aberrant 
activation of Src is implicated in the development and progression of many human 
tumors (Roskoski, 2004). The kinase activity is tightly controlled; fundamental is the 
intramolecular interaction between the phospho-Tyr 527 and the phosphotyrosine-
binding domain SH2 that locks the kinase in an inactive conformation.  The tyrosine 
protein kinase Csk (C-Src kinase) is the enzyme that catalyzes the phosphorylation of 
Src at Tyr-527 and thereby suppresses its activity (Thomas et al., 1991).  
PI3K catalyzes the phosphorylation of the inositol ring of PtdIns at the position 3, 
mainly converting PtdIns(4,5)P2 to PtdIns(3,4,5)P3 (see paragraph I.2 for a detailed 
description of phosphoinositide molecules). PtdIns(3,4,5)P3 is a key second messenger 
that acts as signaling hub in a wide range of cellular programs like cell survival, cell 
growth and cell migration. Therefore sustained PtdIns(3,4,5)P3 signaling is strictly 
associated with tumorigenesis (Yuan and Cantley, 2008). To avoid persistent 
activation, a negative feedback loop ensures that PtdIns(3,4,5)P3 is only transiently 
available at the plasma membrane. For this purpose the phosphatase PTEN catalyzes 
the dephosphorylation of PtdIns(3,4,5)P3 into PtdIns(4,5)P2, extinguishing the signal 
(Carracedo and Pandolfi, 2008). Intriguingly, PRL-3 overexpression triggers the 
 11 
activation of these two oncogenes, promoting the degradation of their negative 
regulators. Indeed, it has been reported that elevated PRL-3 levels correlated with a 
substantial reduction in Csk and PTEN (Liang et al., 2007; Wang et al., 2007). As 
previously mentioned, PRL-3 itself seems to be a substrate of Src, thus a positive 
feedback loop may exist involving Src and PRL-3. As expected, PRL-3-mediated Src 
activation culminated in the persistent phosphorylation of downstream targets of Src 
such as ERK1/2. Interestingly, independent studies have also shown elevated ERK1/2 
phosphorylation in PRL-3 overexpressing cells. However, the authors linked this 
observation with the reduction in integrin β1 phosphorylation (see paragraph I.1.3.F.) 
(Peng et al., 2009). Taking into account the drastic morphological and molecular 
changes needed for cell invasion and motility, it cannot be excluded that PRL-3 
affects multiple input circuits that ensure a robust signaling. Additionally, it has been 
shown that PRL-3 promotes epithelial-mesenchymal transition (EMT) in a PI3K-
dependent manner in DLD-1 human colorectal cancer cells (Wang et al., 2007). The 
EMT is an extremely complex process in which polarized epithelial cells are 
converted into migratory mesenchymal cells. Such long-lasting morphological and 
molecular changes typically occur during development. However, cancer metastasis 
could originate taking advantage of the same molecular machinery (Craene and Berx, 
2013). Thus, PRL-3 overexpression is associated with the downregulation of 
epithelial markers such as E-cadherin, γ-catenin, and integrin β3 (Wang et al., 2007). 
In agreement with these findings, it has been shown that PRL-3 silencing in SW480 
cells correlates with the recovery of E-cadherin expression. Moreover, the authors 
prove a direct interaction between PRL-3 and CDH22 (cadherin 22), a member of the 
cadherin family (Liu et al., 2009). Finally, a significant negative correlation between 
PRL-3 and E-cadherin mRNA levels has been demonstrated in hepatocellular 
carcinoma tumor tissues (Zhao et al., 2008).  
As expected, in DLD-1 cells PRL-3 also up-regulates mesenchymal markers such 
as fibronectin and Snail in a PI3K-dependent manner (Wang et al., 2007). Recently, it 
has been shown that in the region of the PRL-3 promoter three potential binding sites 
for the transcription factor Snail are present. This led the authors to suggest a key role 
of Snail in the regulation of PRL-3 expression in colorectal cancer, opening the 
possibility of an additional positive feedback loop that strengthens PRL-3 signaling 
(Zheng et al., 2011). 
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I.1.3.F. Potential substrates of PRL-3 
Identification of PRL-3 substrates and correlation of these data with the phenotypes 
observed in PRL-3 overexpressig cells is probably, at the moment, one of the most 
challenging undertakings. Several substrates have been suggested for PRL-3, namely 
ezrin, integrin β1, keratin8, nucleolin, stathmin and elongation factor 2 (EF2) (Forte 
et al., 2008; Mizuuchi et al., 2009; Orsatti et al., 2009; Peng et al., 2006, 2009; Semba 
et al., 2010; Tian et al., 2012; Zheng et al., 2010). Ezrin and integrin β1 were shown 
to be directly dephosphorylated by PRL-3 and they will be discussed in detail. For the 
other, a correlation between PRL-3 overexpression and reduced phosphorylation has 
been shown. However, a formal prove that PRL-3 directly dephosphorylates these 
proteins is still missing. Hence, it is not possible to exclude that the reduced 
phosphorylation observed is an indirect effect. 
• Ezrin is a member of the ERM (ezrin/radixin/moesin) family. ERM proteins work 
as molecular crosslinkers between the cell membrane and actin filaments, and are 
involved in a variety of cellular processes such as cell adhesion and cell polarity. 
Their activity is regulated by the state of phosphorylation of Tyr and Thr residues, 
as well as binding to the phosphoinositide PtdIns(4,5)P2 (see paragraph I.2 for a 
detailed description of phosphoinositide molecules). Phosphorylation and 
PtdIns(4,5)P2 binding are together necessary for full molecule opening and 
exposure of the actin binding sites (Neisch and Fehon, 2011). It has been shown in 
vitro and in cells that PRL-3 activity primarily affects the phosphorylation of ezrin 
at Thr567 (Forte et al., 2008). Thus, PRL-3 seems to counteract a crucial step 
necessary for Ezrin opening and activation. However, it cannot be excluded that 
these findings are cell type dependent, considering that in different experimental 
conditions the effect of PRL-3 on ezrin phosphorylation could not be confirmed 
(Mizuuchi et al., 2009). 
• Integrins are a large family of transmembrane proteins that mediate cell-cell and 
cell-matrix interactions. Integrins are always found as heterodimers, containing 
two distinct chains, called the α (alpha) and β (beta) subunits. Structurally, each 
subunit consists of a large extracellular domain, a single transmembrane domain 
and a short cytoplasmic tail that, in the β subunits, can be subjected to 
phosphorylation (Shattil et al., 2010; Takada et al., 2007). PRL-3 seems to be an 
integrin-associated protein, more specifically with integrin α1 and β1 (Peng et al., 
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2006, 2009; Tian et al., 2012). Moreover, PRL-3 is able to dephosphorylate in 
vitro and in vivo Tyr783 in the integrin β1 cytoplasmic tail (Tian et al., 2012). 
However, the biological significance of this activity still remains unclear. 
In conclusion, although several protein substrates have been suggested, it is still not 
possible to describe a complete signaling cascade that could explain the pleiotropic 
phenotypes observed in PRL-3 overexpressing cells.  
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I.2. Phosphoinositides  
I.2.1. The seven distinct phosphoinositide species 
Phosphoinositides comprise a family of phosphorylated derivatives of the membrane 
lipid phosphatidylinositol (PtdIns). Reversible phosphorylation at the 3, 4, and/or 5 
position(s) of the inositol ring generates seven chemically distinct but interconvertible 
phosphoinositide species (Fig. I.4) (Di-Paolo and De Camilli, 2006; Le-Roy and 
Wrana, 2005; Saarikangas et al., 2010; Shewan et al., 2011).  
   
 
 
Figure I.4. Structurs of phosphatidylinositol and its phosphoinositide derivatives. 
Phosphatidyinositol molecules comprise a fatty acid backbone which anchors the 
lipid moiety in the membrane, attached to a inositol ring head, which can be 
reversibly phosphorylated at the 3,4 and/or5 position(s) to generate up to seven 
distinct phosphoinositide species. R and R’ are saturated or unsaturated acyl chains, 
respectively. The total carbon length of R and R’ are in the range of 16-24. Adapted 
from Le Roy and Wrana (2005). 
 
All seven phosphoinositides are minor components of eukaryotic cell membranes. 
Despite their low abundance, phosphoinositides regulate fundamental biological 
processes ranging from membrane trafficking, cytoskeletal organization, to signal 
transduction acting as docking sites for effector molecules and/or precursor of 
secondary messenger (Balla, 2013; Di-Paolo and De Camilli, 2006; Saarikangas et al., 
2010). The involvement of phosphoinositides in such a vast array of biological 
functions is related to a unique set of properties of these molecules:  
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a) Each of the seven phosphoinositides is a distinct cellular signal that is transduced 
by protein effectors able to recognize selectively the distinct phosphorylation sites 
(Fig. I.5) (Kutateladze, 2010). 
        
 
Figure I.5. Phosphoinositide-binding modules. Summary of phosphoinositides 
binding domains and their binding specificity. Frequently, phosphoinositide binding 
proteins are multi-domain proteins that couple the lipid binding with conformational 
changes. These changes can for example modulate the protein enzymatic activity or 
expose a protein-protein interaction motif, leading subsequently to the activation or 
termination of signaling cascades. Notably, the use of fluorescently tagged 
phosphoinositide-binding domains has been a major breakthrough in understanding 
the phosphoinositide’s subcellular distribution and in the visualization of dramatic 
changes in phosphoinositide levels in living cells. Adapted from Kutateladze (2010). 
 
b) Phosphoinositides can be rapidly and sequentially interconverted from one species 
to another by lipid kinases and phosphatases. These phosphoinositide-modifying 
enzymes fine-tune spatially and temporally phosphoinositide levels, maintaining 
cell homeostasis. Additionally, the cleavage of the inositol-phosphate head group 
by phosphoinositide-specific phospholipase C enzymes (PLCs) gives rise to 
metabolites that propagate and amplify signaling. Considering the broad spectrum 
of cellular processes regulated by phosphoinositides, abnormal phosphoinositide 
metabolism is associated with a wide range of human diseases including cancer, 
diabetes and autoimmune disorders (Balla, 2013; Bunney and Katan, 2010; 
Majerus and York, 2009). 
 
c) Each of the seven phosphoinositides has its own distinctive subcellular 
localization, and this lipid signature code is not only fundamental for cellular 
membrane identity but also contributes to spatially restricted downstream 
signaling responses (Fig. I.6) (Kutateladze, 2010). 
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Figure I.6. Subcellular distribution of phosphoinositides. Each of the seven 
phosphoinositides localizes to specific membrane compartments or organelles. 
PtdIns(4,5)P2 and PtdIns(3,4,5)P3 are primarily enriched at the plasma membrane. 
PtdIns(4,5)P2 is constitutively present and is one of the most abundant 
phosphoinositides whereas PtdIns(3,4,5)P3 is typically transient and is rapidly 
degraded following its synthesis. PtdIns(3,4)P2 and PtdIns(3)P are concentrated in 
the early endocytic pathway vesicles and in early endosomes (EE),  respectively. 
PtdIns(3,5)P2 is mostly found in the multivescicular bodies (MVB) and lysosomes 
(late compartments of the endosomal pathway). PtdIns(4)P is enriched at the Golgi 
apparatus. The location of PtdIns(5)P remains poorly characterized. Adapted from 
Kutateladze (2010). 
 
 
I.2.2. Roles of PtdIns(4,5)P2 at the plasma membrane 
PtdIns(4,5)P2 is a multipotent signaling molecule that participates in almost all events  
that occur at the plasma membrane (McLaughlin et al., 2002). It plays a central role in 
signal transduction as precursor of key second messengers, namely Inositol(1,4,5)-
triphosphate (IP3) and diacylglycerol (DAG) upon phospholipase cleavage, or 
PtdIns(3,4,5)P3 during PI3K activation (Berridge and Irvine, 1987; Czech, 2000). On 
the other hand, PtdIns(4,5)P2 directly regulates a plethora of cellular processes 
including exo- and endocytosis, ion channel mediated transport, cytokinesis, cell 
shape, motility, polarity and adhesion through fluctuations of its own levels as well as 
compartmentalization in plasma membrane microdomains (McLaughlin et al., 2002). 
PtdIns(4,5)P2 directly regulates actin cytoskeleton dynamics affecting the function of 
several actin-associated proteins, often in cooperation with small GTPases. Typically, 
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PtdIns(4,5)P2 predisposes the actin cytoskeleton to a “polymerization mode”. Indeed, 
PtdIns(4,5)P2 inhibits actin-binding proteins that disassemble actin filaments, 
promotes nucleation of actin networks and enhances both actin filament cross linking 
and plasma membrane/actin cytoskeleton interactions (Lanier and Gertler, 2000; 
Saarikangas et al., 2010). One classical example of adaptor proteins that link the 
plasma membrane with the actin cytoskeleton in a PtdIns(4,5)P2 –dependent manner 
are the proteins of the ERM family (Neisch and Fehon, 2011), already discussed in 
paragraph I.1.3.F. 
 
I.2.3. Phosphoinositide phosphatases 
Essential to elucidate biological and pathological roles of phosphoinositides is to 
characterize the enzymes involved in their synthesis, interconversion and degradation. 
In mammals close to 50 genes encode for phosphoinositide kinases and 
phosphatases. These phosphoinositide-modifying enzymes allow cells to maintain 
phosphoinositide homeostasis as well as to respond rapidly and selectively to 
environmental changes (Balla, 2013).  
The relevance of phosphoinositide phosphatases in cell homeostasis is highlighted 
by severe genetic disorders that result from mutations in genes encoding this class of 
enzymes. Additionally, many phosphoinositide phosphatases are referred to as 
oncogene or tumor suppressor, considering that somatic mutations in these enzymes 
are key events in cell transformation. Curiously, even if alterations in level or activity 
of phosphoinositide phosphatases often create striking phenotypes in animal models 
or cell culture, in most of the cases the underlying molecular mechanisms remain 
unknown (Majerus and York, 2009). Conventionally, phosphoinositide phosphatases 
can be classified on the basis of their catalytic mechanism of action or on the basis of 
their substrate specificity towards the phosphate in the 3, 4 or 5 positions. According 
to the first classification, historically, mammalian phosphoinositide phosphatases 
belong to two distinct superfamilies: the PTP superfamily (reviewed in paragraph 
I.1.2.) and the inositol polyphosphate 5-phosphatase (5-ptase) superfamily. The 5-
ptases share the same mechanism of catalysis of apurinic/apyrimidinic base excision 
repair endonuclease. The catalysis has been shown to proceed without a 
phosphoenzyme intermediate, with direct transfer of the phosphate group to a 
nucleophilic water molecule (Ooms et al., 2009). In mammals, 10 distinct 5-ptases 
have been identified. These enzymes catalyze the removal of the phosphate in 5-
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position from the inositol ring of PtdIns(4,5)P2, PtdIns(3,4,5)P3, and/or PtdIns(3,5)P2. 
Some members of the family show additionally activity toward soluble inositol 
phosphates. Notably, 5-ptases are multidomain proteins in which subcellular targeting 
motifs such as the CAAX box have been identified (Ooms et al., 2009). 5-ptase type 
IV is one example of a C-terminally prenylated 5-ptase. The enzyme removes the 5-
position phosphate from PtdIns(3,5)P2, PtdIns(4,5)P2 and PtdIns(3,4,5)P3 and on the 
basis of kinetic data is considered to be the most potent PtdIns(3,4,5)P3 phosphatase 
(Kisseleva et al., 2000). Interestingly, 5-ptase type IV knockout mice showed severe 
defects in primary cilia formation associated with multiorgan failure, opening the 
possibility of an additional role of phosphoinositides in ciliary functions (Jacoby et 
al., 2009). Although considerable effort has been directed toward characterizing 
phosphoinositide phosphatases in vivo, studies of phosphoinositides dynamics at the 
subcellular level are still challenging. Thus, most phosphoinositide phosphatases have 
only been characterized in vitro with respect to their substrates, and cell studies are 
often lacking. Thus far, the connection between the physiologic substrates of 
phosphoinositide phosphatases, signaling pathways and human diseases remains for 
most of the phosphatases elusive. We identified PRL-3 as a new PtdIns(4,5)P2  
phosphatase in our in vitro  studies and this argument will be discussed in further 
detail in the result section (Chapter III). Additionally, we characterized the effects of 
PRL-3 over-expression on epithelial morphogensis (Chapter IV), thus the next 
paragraphs will give a brief overview on epithelial organization and cell polarity. 
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I.3. Epithelial organization and cell polarity 
I.3.1. Structure of mammalian epithelial cells 
Epithelial tissues are sheets of epithelial cells tightly packed together that provide a 
barrier between appropriate interfaces. Internal epithelial organs are typically 
constituted by two types of building block, cysts and tubules. Cysts are spherical 
single layers of epithelial cells that surround a central hollow lumen. Tubules are also 
a lumen-enclosing monolayer of polarized epithelial cells but are cylindrical instead 
of spherical. Epithelial organs such as lung or kidney are organized in a network of 
branching tubules that terminate in cysts (Brien et al., 2002). Each cell in mature cysts 
or tubules is polarized, showing three type of plasma membrane domains that are 
morphologically distinct: (i) a free, microvilli-rich apical membrane that faces the 
lumen, (ii) a lateral surface that contacts neighboring cells, and (iii) a basal membrane 
that adheres to the basement membrane, a specialized extracellular matrix (ECM) 
(Fig. I.7) (Brien et al., 2002; St Johnston and Ahringer, 2010). This clear apico-basal 
polarity is marked by the asymmetric distribution of both proteins and lipids across 
the plasma membrane. The apical domain, in contact with the fluid-filled central 
lumen, can contain specialized structures such as microvilli that increase the surface 
area and form the brush border. Under the apical membrane, a thick cortical belt of 
actin is linked to the plasma membrane through ERM family proteins. The lateral 
domain is characterized by the presence of junctional complexes that carry out barrier 
and adhesive functions needed to generate molecular asymmetry and mechanical 
stability, respectively (Brien et al., 2002; McCaffrey and Macara, 2009; Roignot et 
al., 2013). In vertebrates, the epithelial junctional complex comprises desmosomes, 
adherens junctions (AJs) and tight junctions (TJs). Desmosomes and adherens 
junctions carry out adhesive functions, tethering intermediate and actin cytoskeletal 
filaments to the plasma membrane. In both cases, members of the cadherin family 
bridge the adjacent plasma membranes of neighbouring cells via their homophilic 
interactions (Baum and Georgiou, 2011). Tight junctions work as barriers sealing the 
paracellular space and preventing diffusion of membrane components between the 
apical and the basolateral domain. TJs localize at the apico-lateral border and 
demarcate the boundary between the apical and the basolateral domain (see paragraph 
I.3.3.) (Matter and Balda, 2003). Finally, the basal membrane is depleted of 
intercellular adhesion molecules and enriched in integrin and non-integrin receptors 
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such as dystroglycan that anchor cells to the surrounding matrix, transducing basal 
cues to the cytoskeleton (Brien et al., 2002; Datta et al., 2011). 
 
 
 
Figure I.7. Mammalian epithelial cell architecture. Schematic representation of a 
polarized epithelial cell specialized in absorptive functions. Each cell presents three 
distinct plasma membrane domains: an apical membrane, directly in contact with the 
luminal space, a lateral membrane that adheres to the flanking cells and a basal 
membrane that anchors the cell to the extracellular matrix (ECM). Epithelial cells are 
joined to each other via the “apical junctional complex” that comprises: tight 
junctions (TJs), adherens junctions (AJs) and desmosome. Notably, TJs and AJs are 
linked to the actin cytoskeleton; desmosomes are linked to intermediate filaments. 
Adapted from Matter and Balda (2003). 
 
I.3.2. Phosphoinositides as polarity signals 
Apico-basal polarization requires compartmentalization not only of proteins but also 
of lipids, particularly phosphoinositides. Phosphoinositides themselves, being 
asymmetrically distributed across the plasma membrane, are crucial determinants of 
apical and basolateral membrane identity (Shewan et al., 2011). Specifically, 
PtdIns(3,4,5)P3 is restricted to the basolateral domain, being selectively excluded from 
the apical surface, whereas PtdIns(4,5)P2 localizes all over the plasma membrane but 
is enriched at the apical surface (Gassama-Diagne et al., 2006; Martin-belmonte et al., 
2007). The differential distribution of phosphoinositides on the plasma membrane is 
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fundamental for establishment and maintenance of polarity, recruiting asymmetrically 
lipid-binding proteins. It has been shown that lipid segregation proceeds in concert 
with junction assembly through the recruitment of PTEN at the apical border via 
direct interaction with the tight junction protein Par3. PTEN, converting 
PtdIns(3,4,5)P3 to PtdIns(4,5)P2, acts as a barrier to prevent PtdIns(3,4,5)P3 diffusion 
in the apical domain (Comer and Parent, 2007; Datta et al., 2011; Martin-belmonte et 
al., 2007). The PtdIns(4,5)P2 – dependent pathway, involved in apical domain 
specification, will be discussed in detail in the paragraph I.3.6. 
 
I.3.3. Structure and composition of epithelial tight junctions 
Tight junctions localize at the lateral-apical border of epithelial cells and function as a 
barrier restricting protein and lipid movements between the apical and  basolateral 
compartments and selectively sealing the space between neighboring cells (Matter 
and Balda, 2003). Epithelial TJs are formed by evolutionary conserved multiprotein 
complexes. It is possible to distinguish two major groups of junctional proteins: the 
transmembrane proteins and the cytoplasmic “plaque”. Transmembrane proteins such 
as occludin, claudin and JAMs (junctional adhesion molecules) mediate cell-cell 
adhesion and constituite a selective paracellular diffusion barrier. The cytoplasmic 
plaque contains functionally distinct complexes that include adaptors, regulatory and 
signaling proteins. Adaptors are able to bind directly the TJ transmembrane 
components and, in turn, recruit regulatory proteins such as kinases, phosphatases and 
GTPases at the TJ site. Adaptors are usually multidomain proteins characterized by 
several protein-protein interaction modules such as the PDZ domain. Among the 
adaptors, the zona occludens (ZO) proteins are involved in the clustering of 
transmembrane proteins, binding the cytoplasmic tail of claudin and occludin via their 
PDZ domains. In addition, several components of the cytoplasmic plaque and the 
transmembrane protein occludin contact the actin cytoskeleton, functioning as plasma 
membrane-actin cytoskeleton linkers (Paris et al., 2008; Schulzke and Fromm, 2009; 
Shin et al., 2006).    
 
I.3.4. The PAR-aPKC polarity complex 
Essential for epithelial cells polarization is the coupling of the PAR-aPKC polarity 
complex to junctional structures. The Par3-Par6-aPKC complex (where Par is for 
“partitioning defective” and aPKC is for “ atypical protein kinase C) are a set of 
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evolutionary conserved proteins involved in cell polarity in various biological 
contexts (St Johnston and Ahringer, 2010). Both Par3 and Par6 are PDZ domain-
containing scaffold proteins that work as adaptors at the TJ site; aPKC isoforms 
(PKCζ and PKCι in human) are serine/threonine protein kinases, which share a 
calcium- and diacylglycerol- independent mechanism of activation. Par3, Par6 and 
aPKC form a physical complex by multiple direct interactions. Notably, the complex 
does not assemble in a constitutive manner but is subjected to multiple levels of 
regulation (Fig. I.8). Indeed, Par3 is primarily recruited to the primordial adhesion 
sites through the interaction with adhesion complex proteins and JAM proteins, 
whereas Par6/aPKC recruitment relies on Cdc42 activation. More specifically, GTP-
bound Cdc42 associates with the Par6/aPKC complex by direct binding to Par6 and 
leads, in turn, to the activation of aPKC. Subsequently, the active Par6-aPKC 
complex is recruited at the TJ site through multiple interactions with the scaffold 
Par3. This model suggests a simple mechanism of specific aPKC activation within a 
cell in which the kinase activity is timely regulated subsequent to Cdc42 activation. 
Thus, the complex, asymmetrically localized, promotes TJ maturation and thereby 
contributes to the separation of the apical and basolateral domain (Aranda et al., 2008; 
Suzuki and Ohno, 2006). Additionally, Par3 holds at the TJ site the RAC exchange 
factor TIAM1, necessary for RAC-mediated assembly of the actin ring at the cell 
cortex, and the lipid phosphatase PTEN, necessary to induce phosphoinositides 
asymmetry at the plasma membrane (Chen and Macara, 2005; Feng et al., 2008).  
Notably, in fully polarized epithelial cells, Par3 does not strictly colocalize with Par6 
and aPKC. Indeed, Par6 and aPKC are restricted to the apical domain whereas Par3 
maintains TJ localization (Martin-belmonte et al., 2007).    
 
I.3.5. Three-dimensional (3D) epithelial cultures: a tool for studying epithelial 
architecture 
In vitro studies of epithelial cells cultured on plastic or glass bottom dishes (two-
dimensional (2D) cultures) have revaled important mechanisms and molecular 
pathways required for cell polarization. However, 2D cultures might not successfully 
recapitulate the physiological characteristics distinctive of epithelial cells in vivo.  
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Figure I.8. Domain architecture of the Par3/Par6/aPKC polarity complex. Par6 and 
aPKC are constitutively associated through their N-terminal PB1 (Phox and Bem1p 
1) domains and this conformation inhibits the basal activity of aPKC. Par6 contains, 
in addition to the PB1 domain, a semi-CRIB (Cdc42/Rac interactive binding) motif 
and a single PDZ (PSD95/Dlg/ZO-1) domain. Upon Cdc42 activation, GTP-bound 
Cdc42 is able to associate with Par6, binding simultaneously the semi-CRIB motif 
and the contiguous PDZ domain. The binding of Cdc42 to Par6 induces a 
conformational change that allows the activation of the associated aPKC (Lin et al., 
2000). Par3 is characterized by an amino-terminal conserved region 1(CR1) domain 
responsible for Par3 self-oligomerization (Mizuno et al., 2003), three central PDZ 
domains that mediate protein-protein or protein-lipid interactions and the C-terminal 
region containing the aPKC-binding motif. It has been shown that Par3 can associate 
with Par6 through a PDZ-PDZ interaction (first PDZ domain of Par3), as well as 
with aPKC, binding directly its kinase domain. The second PDZ domain of Par3 
binds with high affinity phosphoinositides and this interaction is essential for Par3 
plasma membrane localization (Wu et al., 2007). Finally, the third PDZ domain of 
Par3 binds the lipid phosphatase PTEN (Feng et al., 2008). Interestingly, Par3 itself 
is a substrate of aPKC and its phosphoryalation lowers the affinity between Par3 and 
Par6/aPKC (Nagai-tamai et al., 2002). In the figure, domain interactions are 
indicated by dashed lines. Adapted from Nakayama et al. (2008) 
 
Indeed, epithelial cells grown on plastic substrates show a considerably different 
morphology as compared to the epithelium in vivo, becoming partially depolarized 
and rather flat. Responsible for such different morphology is the lack of a three-
dimensional (3D) microenvironment and therefore the signaling pathways generated 
by cell-matrix and cell-cell adhesion. Thus, in the last two decades considerable 
efforts have been made to develop cell culture conditions more representative of an 
“in-vivo-like” environment. The best results have been obtained with the growth of 
epithelial cells in 3D gels of ECM such as the Matrigel (solubilized basement 
membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse 
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sarcoma). Selected epithelial cells, both from primary cultures and established lines, 
are able to form complex epithelial structures that share the same key features of in 
vivo glandular epithelial organs when grown in 3D cultures (Zegers et al., 2003). Two 
widely used cell lines are the MDCK, canine kidney epithelial cells and MCF10A 
human breast cells. Both cell lines, cultured in presence of the 3D matrix, can form 
spheroid structures, variably named cysts or acini according to the epithelial cell 
origin (Debnath and Brugge, 2005). More specifically, MDCK cells in 3D cultures 
form cyst-like spherical structures in which a single layer of polarized epithelial cells 
encloses a central hollow lumen. Each cell in the cyst shows a clear apicobasal 
polarization with its apical surface facing the central fluid-filled lumen, its basal 
membrane in contact with the ECM and mature tight junctions delimiting the 
lateral/apical border (Schlüter and Margolis, 2009).  Moreover, 3D epithelial culture 
systems not only permit to mimic epithelial cell architecture but also to apply cellular 
and molecular biology tools (i.e., cDNA overexpression, RNA interference, imaging). 
Thus, 3D cell cultures were shown to be a powerful system to decipher the molecular 
and cellular aspects of epithelial morphogenesis, such as the molecular pathways 
regulating lumen establishment and maintenance, as well as to investigate the 
mechanism associated with epithelial tumor initiation and progression (Brien et al., 
2002; Debnath and Brugge, 2005). These arguments will be discussed in detail in the 
following sections. 
 
I.3.6. De Novo lumen generation 
During development, tubular structures can originate through remarkably different 
mechanisms. Tubules can arise by mechanical deformation of epithelial sheets, or 
they can originate by conversion of poorly adherent mesenchymal cells into polarized, 
tightly connected epithelial cells (mesenchymal-epithelial transition). In the first case, 
existing epithelial sheets rearrange in the course of major morphogenetic movements 
to give rise to hollow tubes. In the second case, groups of cells rapidly polarize and 
generate a central lumen de novo (Lubarsky and Krasnow, 2003). Two mechanisms of 
de novo lumen generation have been predominantly observed: cavitation and 
hollowing (Fig. I.9) (Bryant and Mostov, 2008; Datta et al., 2011). During cavitation, 
the lumen is formed by selective apoptosis of the inner cell population that is not in 
contact with the ECM, whereas the outer layer of cells, connected to the matrix, 
progressively polarizes. This process has been described, for example, in 3D culture 
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of MCF-10A during acinar morphogenesis, and in vivo during mammary gland 
development (Debnath et al., 2002; Humphreys et al., 1996; Mailleux et al., 2007). In 
the hollowing mechanism instead, polarization is generated by membrane domain 
separation coupled to polarized exocytosis. Thus, during hollowing, cells acquire 
apical-basal polarity de novo, assemble cell-cell junctions and form initially a small 
lumen in the center of the system between closely apposed cells that subsequently 
expands by fluid and ion efflux. This mechanism has been observed in 3D culture of 
MDCK during cystogenesis as well as in vivo during zebrafish gut development 
(Apodaca et al., 2012; Bagnat et al., 2007; Bryant and Mostov, 2008; Datta et al., 
2011). The molecular pathways behind the hollowing mechanism will be described in 
the next paragraph.   
 
 
 
Figure I.9. Mechanisms of de novo lumen formation. Two distinct mechanisms of 
de novo lumen formation, namely cavitation and hollowing, have been predominantly 
observed when cysts or tubules originate from poorly polarized cell aggregates. 
During cavitation, de novo lumen formation requires survival and polarization of the 
ECM-contacting cells in the periphery as well as selective apoptosis of the inner cells 
mass. During hollowing, cells precociously establish the axis of polarity. This process 
requires ECM-ECM receptors interactions, intracellular vesicles delivery of apical 
membrane determinant to the center of the system as well as phosphoinositide 
segregation in order to establish membrane identity. Once a rudimentary lumen is 
formed, tight junctions, pump proteins and possibly ezrin promote lumen expansion. 
Adapted from Bryant and Mostov (2008). 
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I.3.7. The hollowing mechanism: molecular regulation of lumen morphogensis 
When tubular epithelia are formed de novo from non-polarized cells, combinatorial 
inputs provide the molecular cues necessary to establish apicobasal polarization and 
thus the spatial coordinates for determining the direction of lumenogenesis.  
The initial cue derives from protein of the basal lamina (specialized ECM), in 
particular laminins and collagen IV that provide one axis from which to orient lumen 
position. Indeed lumens originate in most cases perpendicularly to the ECM-
contacting membrane, with the exception of hepatocytes where lumens originate 
laterally between cells (Cohen et al., 2004; Datta et al., 2011; Treyer and Müsch, 
2013). It has been demonstrated that integrin β1 plays a critical role in mediating cell-
ECM interactions and thus to correctly orient polarity. In detail, in 3D culture of 
MDCK cells it has been shown that the pathway laminin-integrin β1-Rac1 controls 
apicobasal polarization by influencing cytoskeletal tension (O’Brien et al., 2001; Yu 
et al., 2005). The second spatial cues come from cell-cell interactions through the 
formation of intercellular junctions (Datta et al., 2011). Cell-cell contact occurs via a 
multitude of adhesion molecules, including cadherins (epithelial junctional complexes 
were already discussed in paragraph I.3.1 and I.3.3.). It has been observed that the 
process of polarization in MDCK cysts starts in a very early stage, immediately after 
the first cytokinesis (Schlu et al., 2009). Once newly polarizing cells establish the axis 
of polarity, recognizing the ECM and assembling primordial junctions, luminal space 
can be generated. In MDCK cysts, one of the earliest intermediate in luminogenesis 
described is the specification of the “apical membrane initiation site” (AMIS) 
(Apodaca, 2010; Bryant et al., 2010). The AMIS is a specialized membrane domain at 
the zone of cell-cell contact, in the core region of the nascent cyst, in which key apical 
determinants such as polarity and trafficking proteins are transiently enriched. This 
region is established before a tight junction-demarcated lumen can be observed and is 
the site where the lumen will subsequently open. Therefore, selective delivery of 
vesicles containing apical determinants to a discrete common landmark (the AMIS) is 
the critical step that specifies lumen position. This process, named polarized 
exocytosis, is governed by the small GTPases of the Rab family, which regulate cargo 
selection, vesicle maturation and vesicle tethering with target membranes (Apodaca, 
2010; Bryant et al., 2010). Fundamental for polarized traffic is also the role of the 
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cytoskeleton, in particular the directional transport along microtubules that is directed 
by several proteins of the kinesin family. For the transport of apical cargo the kinesin 
Kifc3, Kif5B and Kif17 were demonstrated to be primarily involved (Jaulin and 
Kreitzer, 2010; Jaulin et al., 2007; Noda et al., 2001). Finally, vesicles fusion is 
mediated by t-SNAREs proteins, including syntaxin-1,-2 and -3 (Sharma et al., 2006; 
Torkko et al., 2008). Studies on 3D culture of MDCK cells have revealed that the 
transition between unpolarized epithelia to cysts starts precociously, right after the 
first cytokinesis, at the two-cell stage (Schlu et al., 2009). At this stage, several apical 
signaling molecules are still not properly compartmentalized, showing a diffuse 
staining all over the plasma membrane, or localizing mainly at the ECM-contacting 
plasma membrane. Apico-basal polarization is rapidly established through 
transcytosis of apical determinants from the basolateral membrane to the forming 
luminal surface. This directional transport relies on the Rab11a-Rabin8α-Rab8a 
cascade (Fig. I.10). Indeed, apical determinants are initially internalized from the 
basolateral membrane into Rab11a positive vesicles to which Rab8a is recruited 
through the Rab guanine nucleotide exchange factor (GEF) Rabin8. This Rab cascade 
is responsible for vesicle delivery, probably by regulating motor proteins such as 
myosin-5B (Apodaca et al., 2012; Bryant et al., 2010). Subsequently, the hetero-
octameric exocyst complex mediates the docking and tethering of apical cargo to the 
target membrane to create the AMIS. Notably, exocyst subunits show a non-
overlapping subcellular distribution during polarized exocytosis, with Sec15a 
recruited to the Rab11a-positive vesicles whereas Sec10 and Sec8 are localized on the 
target membrane, underlying the lumen initiation site. Therefore, the interaction 
between the vesicular Sec15a and the membrane localized Sec10 may promote the 
accurate docking of apical cargo to the AMIS (Bryant et al., 2010; He and Guo, 
2009). Finally, in MDCK cystogenesis, the exocyst complex is also important for the 
recruitment of the Par3-aPKC complex to the AMIS, through the direct binding of 
Sec8 to Par3 (Apodaca, 2010; Bryant et al., 2010; Zuo et al., 2009). Moreover, the 
Cdc42-GEF Tuba, responsible for Cdc42 activation, is also recruited on apical 
vesicles in an active Rab8–dependent manner.  Thus, polarized trafficking contributes 
to this initial step of lumenogenesis by promoting compartmentalization of the Par3-
aPKC complex as well as by activation of Cdc42 specifically at the apical membrane 
(Apodaca, 2010; Bryant et al., 2010). In conclusion, it has been shown that during the 
 28 
early phase of lumenogensis, the robust crosstalk between the trafficking and the 
polarity machinery is fundamental to establish and maintain the apical domain.  
Once the AMIS has been established, lumenogenesis proceeds with lumen 
maturation. This transition is characterized by the relocalization of Par3 and the 
plasma membrane-associated exocysts subunits Sec8 and Sec10 to the tight junction 
regions (Bryant et al., 2010). 
 
 
Figure I.10. Molecular machinery required for de novo lumen formation. Apical 
determinants like the sialoglycoprotein podocalyxin, are rapidly internalized from the 
ECM-contacting plasma membrane into Rab11a positive vesicles. Polarized 
trafficking of apical cargo requires the recruitment and activation of Rab8, through 
the GEF Rabin8α, to the apical vesicles. Vesicle exocytosis is promoted by the Rab- 
dependent recruitment of the exocyst complex subunit Sec15A, which will drive the 
selective docking of apical cargo to the AMIS, where the other exocyst subunits Sec8 
and Sec10 are already localized. Trafficking and polarity machinery are robustly 
linked together at multiple levels. Indeed, the exocyst subunit Sec8 restricts the 
localization of the Par3-aPKC complex to the AMIS; moreover, the Rab8-dependent 
recruitment of the Cdc42-GEF Tuba to the apical vesicles promotes Cdc42 activation, 
leading, in conclusion, to the specific delivery of active Cdc42 to the AMIS. Adapted 
from Bryant et al. (2010).  
 
As previously mentioned, apico-basal polarization relies on the asymmetric 
distribution of both proteins and lipids. In MDCK cysts, the compartmentalization of 
phosphoinositides is a crucial step to generate membrane identity. Exclusion of 
PtdIns(3,4,5)P3 from the apical surface is governed by the lipid phosphatase PTEN, 
which metabolizes PtdIns(3,4,5)P3 into PtdIns(4,5)P2 and may also participate in the 
PtdIns(4,5)P2-enrichment observed at the luminal surface (Martin-belmonte et al., 
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2007). Strikingly, during cysts development, PTEN localizes at the tight junction 
border through a direct binding with Par3, which partially explains how 
basolateral/apical phosphoinositide asymmetry has been generated (Feng et al., 2008; 
Martin-belmonte et al., 2007). Although it is likely that the PtdIns(4,5)P2/ 
PtdIns(3,4,5)P3 differential distribution reinforces cell polarization by selective 
recruitment of key effecting proteins on separate membrane domains, the identity of 
these targets is still unknown.  
Notably, it has been reported that the PtdIns(4,5)P2-binding protein Anx2 
(AnnexinA2) in the early stage of luminogenesis localizes on Rab11a positive 
vesicles, where it promotes the recruitment of Cdc42 (Bryant et al., 2010). However, 
whether PtdIns(4,5)P2 is directly enriched at the AMIS, taking advantage of the fusion 
of vesicles, has not yet been demonstrated. Finally, the last step of de novo lumen 
formation is the physical opening of the lumen. This stage seems to be governed by 
apical delivery and activation of pumps and channels as well as by proteins 
characterized by anti-adhesive properties (Bryant and Mostov, 2008). Generally, 
proteins with antiadhesive properties, as for example the apical determinant 
podocalyxin, carry in their extracellular domains highly negatively charged groups, as 
for example glycosyl and/or sialyl moieties (Meder et al., 2005). Thus, at the moment, 
it is suggested that the electrostatic repulsion from opposing plasma membrane is the 
initial step that generates extracellular space necessary for subsequent lumen 
expansion.  
 
I.3.8. Reconstruction of tumor phenotypes in 3D culture 
In the above paragraph several key molecular regulators governing de novo formation 
of the lumen have been described. Notably, understanding the molecular mechanisms 
beyond lumen formation and maintenance is not only crucial for our comprehension 
of these morphogenic processes during development but also to shed light into the 
molecular alterations connected with luminal networks dysfunction in common 
human diseases. In particular, loss of polarity and luminal filling are considered key 
steps during glandular epithelial organ tumorigenesis, such as in the ductal carcinoma 
in situ (pre-invasive breast cancer) (Burstein et al., 2004). 3D epithelial cell culture 
systems were shown to be precious cell models to investigate the role of cancer genes 
and pathways involved in epithelial architecture disruption during tumorigenesis 
(Debnath and Brugge, 2005). One possible strategy is to mimic tumor phenotypes by 
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manipulating the expression of genes using molecular biology tools (i.e. RNA 
interference, cDNA overexpression). In general, studies on 3D culture have permitted 
to model several events associated with epithelial transformation, including loss of 
cell adhesion and polarity, filling of the luminal space, escape from apoptosis and 
invasive behavior (Debnath and Brugge, 2005). For example, in a series of elegant 
experiments using 3D culture of non-transformed human mammary epithelial cells 
(MCF10A), C. T. Leung and J. S. Brugge have dissected the process by which 
sporadic oncogenic mutations could initiate clonal cancer progression in the early 
stages of human breast tumorigenesis. More specifically, the authors have evaluated 
the effects of a single oncogene-expressing cell in the context of a tightly regulated 
epithelial architecture. Notably, overexpression of classical oncogenes, such as the 
transcription factor Myc or the constitutively active kinase AKT, is not able to drive 
clonal outgrowth (Fig. I.11). These data indicate that within acinar structures 
oncogenic mutations could remain quiescent, highlighting the suppressive influence 
of an organized epithelial environment on initial neoplastic stages. By contrast, 
overexpression of ERBB2, a tyrosine kinase receptor classically found amplified in 
breast tumors, is sufficient to drive cell translocation in the luminal space (lumen 
filling) and clonal outgrowth (Fig. I.11). Moreover, the forced translocation of 
quiescent, oncogene-expressing cells to the luminal space correlates with their 
survival and expansion, lacking the suppressive effect of the neighboring cells. In 
conclusion, the authors propose a model in which cell translocation to the luminal 
space could be the trigger that initiates neoplastic progression (Leung and Brugge, 
2012).    
 
Figure I.11. Single oncogene-expressing cell in mammary acinar culture. Single 
cells overexpressing the oncogenic transcription factor Myc or the myristoylated 
(constitutively active) form of AKT1 kinase remain quiescent in the 3D architecture of 
mammary acini. In contrast, overexpression of the tyrosine kinase receptor ERBB2 is 
associated with lumen filling, with cells actively protruding inside the luminal space. 
Reprinted by permission from Macmillan Publishers Ltd: Leung and Brugge, 
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copyright 2012, Nature Publishing Group. 
 
I.3.9. Functions of the exocyst complex beyond cell polarity 
As already described in the context of lumenogenesis, the polarized trafficking of 
apical determinants is a crucial step in lumen specification that strictly requires the 
exocyst complex. Besides its function in cell polarity, studies in other systems 
indicate that the exocyst tethering complex might have additional roles. Indeed, the 
complex regulates the interaction of vesicles with their target plasma membrane and 
controls different aspects of cell physiology, including abscission (Gromley et al., 
2005; Neto and Gould, 2011). Abscission is the final stage of cyokinesis when the 
plasma membrane of the two daughter cells is physically divided and occurs, as 
lumenogenesis, through targeting and fusion of exocyst vesicles with the intracellular-
bridge plasma membrane (Neto and Gould, 2011). Indeed, several subunits of the 
exocyst complex, including Sec8, are localized at the ring-like structure, named 
midbody, that connects the two daughter cells during abscission (Chen et al., 2013; 
Gromley et al., 2005). Considering that in MDCK cells cyst lumenogenesis starts 
right after the first cell division, it is attractive to speculate that the exocyst complex 
might work as the first landmark for the formation of specialized membrane domains. 
This argument will be examined in more detail in the result (Chapter IV) and 
discussion (Chapter V) sections.  
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Chapter II: Objectives of the research 
 
PRL-3 is a dual specificity phosphatase suspected to play a causative role in the 
development of cancer metastasis when aberrantly overexpressed. To date, the 
molecular basis of PRL-3 functions and its putative substrate(s) remain elusive, 
making it impossible to dissect the mechanism by which PRL-3 overexpression 
promotes cellular metastasis. Moreover, cell culture studies have revealed that the 
aberrant expression of PRL-3 results in a wide range of pleiotropic effects, leading to 
the activation of a multitude of cellular oncogenic pathways. At the start of my 
research project a phosphopeptide library was screened to identify novel candidate 
PRL-3 substrates. This analysis showed no detectable activity of PRL-3 against any of 
the phosphopeptides. On the contrary, preliminary results were suggesting catalytic 
activity toward phosphoinositides. Therefore, the main goal of my thesis was to gain 
more insight into PRL-3 lipid phosphatase activity. Moreover, considering the 
pleiotropic effects of PRL-3 overexpression in standard cell culture conditions, I 
wanted to explore the impact of PRL-3 overexpression in an organotypic 3D cell 
culture model. The underlying idea was to use this system to shed light into the 
mechanism(s) by which PRL-3 promotes metastasis of epithelium-derived cancers in 
a context were PRL-3 overexpression is the dominant oncogenic lesion.  
 
In chapter III, entitled “The Metastasis-Promoting Phosphatase PRL-3 Shows Activity 
toward Phosphoinositides” PRL-3 catalytic activity against phosphoinositides was 
studied. For this purpose, the wild-type (WT) protein and several variants carrying 
mutations in key catalytic residues were tested in vitro using two complementary 
biochemical assays for substrate specificity and activity toward phosphoinositides. 
The data were additionally supported by molecular docking studies, analysis of the 
structural stability of the protein variants and migration assays. 
 
In chapter IV, entitled “The Metastasis-Promoting Phosphatase PRL-3 affects 
epithelial cell polarization by altering post-mitotic midbody fate” the effect of PRL-3 
aberrant overexpression was examined in the context of an organotypic 3D cell 
culture model. Next, the observed phenotypes were extensively characterized by 
imaging and biochemistry techniques. Finally, analyzing the PRL-3-mediated 
phenotype, new insights into the process of lumenogenesis were made.
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Chapter III: The Metastasis-Promoting Phosphatase PRL-3 Shows 
Activity toward Phosphoinositides 
 
 
 
Reprinted with permission from: 
 
Victoria McParland, * Giulia Varsano, * Xun Li, Janet Thornton, Jancy Baby, Ajay 
Aravind, Christoph Meyer, Karolina Pavic, Pablo Rios, and Maja Köhn. (2011). 
 
Biochemistry 50, 7579–7590. 
Copyright 2011 American Chemical Society 
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III.1. Abstract 
Phosphatase of regenerating liver 3 (PRL-3) is suggested as a biomarker and 
therapeutic target in several cancers. It has a well-established causative role in cancer 
metastasis. However, little is known about its natural substrates, pathways, and 
biological functions, and only a few protein substrates have been suggested so far. To 
improve our understanding of the substrate specificity and molecular determinants of 
PRL-3 activity, the wild-type (WT) protein, two supposedly catalytically inactive 
mutants D72A and C104S, and the reported hyperactive mutant A111S were tested in 
vitro for substrate specificity and activity toward phosphopeptides and 
phosphoinositides (PIPs), their structural stability, and their ability to promote cell 
migration using stable HEK293 cell lines. We discovered that WT PRL-3 does not 
dephosphorylate the tested phosphopeptides in vitro. However, as shown by two 
complementary biochemical assays, PRL-3 is active toward the phosphoinositide 
PI(4,5)P2. Our experimental results substantiated by molecular docking studies 
suggest that PRL-3 is a phosphatidylinositol 5-phosphatase. The C104S variant was 
shown to be not only catalytically inactive but also structurally destabilized and 
unable to promote cell migration, whereas WT PRL-3 promotes cell migration. The 
D72A mutant is structurally stable and does not dephosphorylate the unnatural 
substrate 3- O-methylfluorescein phosphate (OMFP). However, we observed residual 
in vitro activity of D72A against PI(4,5)P2, and in accordance with this, it exhibits the 
same cellular phenotype as WT PRL-3. Our analysis of the A111S variant shows that 
the hyperactivity toward the unnatural OMFP substrate is not apparent in 
dephosphorylation assays with phosphoinositides: the mutant is completely inactive 
against PIPs. We observed significant structural destabilization of this variant. The 
cellular phenotype of this mutant equals that of the catalytically inactive C104S 
mutant. These results provide a possible explanation for the absence of the conserved 
Ser of the PTP catalytic motif in the PRL family. The correlation of the phosphatase 
activity toward PI(4,5)P2 with the observed phenotypes for WT PRL-3 and the 
mutants suggests a link between the PI(4,5)P2 dephosphorylation by PRL-3 and its 
role in cell migration. 
 
III.2. Introduction 
Dual-specificity phosphatases (DSPs) belong to the superfamily of protein tyrosine 
phosphatases (PTPs). Classical PTPs remove a phosphate from tyrosine residues of 
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proteins, whereas DSPs exhibit activity toward a variety of different substrates such 
as phosphoserine, -threonine, and -tyrosine but also phosphatidylinositol phosphates 
(PIPs). The DSP PRL-3 is a cancer biomarker and promising therapeutic target.1,2 
PRL-3 is involved in cell growth, proliferation, and invasion,1−4 and it is consistently 
overexpressed in colorectal cancer metastases.5 It has also been shown to play a 
causative role in other cancer types and to correlate with increased metastatic 
potential and poorer prognoses.1,2 In normal tissue, it is expressed at basal levels in 
skeletal muscle and the heart.1 It contains a C-terminal CAAX box (where C is 
cysteine, A an aliphatic amino acid, and X any amino acid), which is farnesylated in 
vivo and localizes PRL-3 to inner membranes, particularly the plasma membrane and 
early endosome.1 This is a unique feature among PTPs; however, it is a common 
feature among inositol phosphatases.6 One of the DSPs structurally most similar to 
PRL-3 is PTEN,7 and the sequence homology between the two (Figure III.1) has 
already been recognized in early molecular cloning studies.8 PTEN is a DSP with 
activity toward 3-phosphorylated PIPs, particularly PI(3,4,5)P3.9 Studies in cell lines 
that stably express ectopic PRL-3 prove a direct correlation between elevated PRL- 3 
levels and the acquisition of a migratory and invasive phenotype.1,2 However, until 
now, the underlying biochemical mechanisms are still widely unknown.1,2 So far, only 
a limited number of proteins have been suggested as natural substrates: Ezrin,10,11 
Keratin 8,12 Integrinβ1,13,14 and Stathmin.15 Integrinα1 has been described as a direct 
interaction partner of PRL-3.13 PRL-3 has been reported to regulate Rho family 
GTPases16,17 and to be involved in downregulating Csk (C- terminal Src kinase) 
leading to Src kinase activation18 via eIF2 using a general mechanism of inhibition of 
protein translation.19 PRL-3 activity in cancer has also been linked to the PTEN-PI3K 
pathway potentially as an upstream posttranscriptional negative regulator of PTEN 
translation to promote epithelial-mesenchymal transition (EMT).16 In addition, PRL-3 
has been shown to promote EMT by direct regulation of Cadherin.20 Unfortunately, 
the suggested substrates have so far not been placed into direct context with the 
pathways affected by PRL-3. Because PRL-3's natural substrates remain unclear and 
the enzyme so far could not be placed conclusively into any signaling pathway, we 
sought to map PRL-3's substrate specificity in vitro and to investigate the 
structure−activity relationship of PRL-3 toward potential substrates by investigating 
key PRL-3 variants. Thereby, we analyzed wild-type (WT) PRL-3 and three PRL-3 
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variants known to affect the catalytic activity of the enzyme: C104S, D72A, and 
A111S (Figure III.1). 
First, the phosphatase activity of these variants was compared using OMFP as a 
substrate,21 and far-UV circular dichroism (CD) spectra were acquired, including 
melting temperatures, to analyze the secondary structure of the variants.22 The PRL-3 
variants were then further characterized with respect to their phosphatase activity 
toward phosphopeptides and phosphoinositides. The chosen peptides were designed 
on the basis of proteins reported to be potential natural substrates. PRL-3 did not 
show any significant activity toward the phosphopeptides. Phosphoinositide activity 
for PRL-3 has not yet been reported.23 We discovered that PRL-3 dephosphorylates 
PI(4,5)P2 and, to a lesser extent, PI(3,4,5)P3 in vitro. Our data, including 
dephosphorylation assays and molecular modeling, suggest that PRL-3 is a 
phosphatidylinositol 5- phosphatase. Subsequently, the cellular phenotype of WT 
PRL- 3 and the variants with respect to promoting cell migration in a wound healing 
assay was investigated using stably transfected HEK293 cell lines. The cellular 
phenotype that we observed correlates well with the structure−activity analysis of all 
variants and the WT protein. Thus, we can suggest that PRL-3's role in cell migration 
can be related to its ability to dephosphorylate PI(4,5)P2 or PI(3,4,5)P3. 
 
 
 
Figure III.1. Sequence and structural alignment of PRL-3 with PTEN.21 The 
mutated residues in PRL-3 used in this study are colored purple (D72, C104, and 
A111). Catalytic residues are underlined. Secondary structures are labeled according 
to PDB entries 1V3A and 1D5R (α-helix, red band; β-sheet, green arrow). 
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III.3. Materials and methods 
III.3.1. Materials 
Fmoc-protected amino acids HBTU, HOBt, and Rink amide resin were purchased 
from Calbiochem. DMF, piperidine, and DCM were purchased from VWR. 
Glutathione S-transferase (GSTrap FF, 1 mL) and NiNTA purification columns were 
purchased from Amersham Biosciences/GE Life Science. Protease inhibitor cocktail 
tablets were purchased from Roche. The EnzChek phosphatase assay kit was 
purchased from Molecular Probes. All soluble di-C8-D-myophosphatidylinositol 
phosphates were purchased from Echelon Biosciences. All other reagents were 
purchased from Sigma-Aldrich. 
 
III.3.2. Bacterial Strains and Plasmid Vectors 
Plasmid vector pET15b was used to overexpress recombinant human WT and mutant 
PRL-3 forms as His-tagged fusion proteins, and vector T7-7 was used to overexpress 
human His-tagged PTP1B. Human PTEN and human type IV 5-phosphatase (5-ptase) 
were overexpressed as GST-tagged fusion proteins using pGEX-4T-1 and pBADM-
30, respectively, as vectors. All recombinant proteins were transformed into 
Escherichia coli strain BL21 DE3 using standard methods that have been previously 
described.24 Bacterial cultures were grown at 37 °C with shaking, and protein 
expression was induced with 0.1 mM IPTG for PRL-3 variants and PTEN and 0.2% 
arabinose for 5-ptase. Proteins were induced for 3 h at 37 °C. 
 
III.3.3. Construction of Mutant PRL-3 Proteins 
A111S PRL-3, C104S PRL-3, and D72A PRL-3 proteins were constructed using 
single-step polymerase chain reaction using complementary primers encoding the 
codon change. Primers 5′ ggcctgggccggtctccagtccttg 3′ and 5′ 
caaggactggagaccggcccaggcc 3 ′ were used to construct A111S . Primers 5 ′ 
cgtttgacgctggggcgcc 3′ and 5′ ggcgccccagcgtcaaacg 3′ were used to construct D72A. 
Primers 5′ ctgtgcactccgtggcggg 3′ and 5′ cccgccacggagtgcacag 3′ were used to 
construct C104S. Mutant constructs were confirmed by DNA sequencing. 
 
III.3.4. Expression and Purification of Recombinant Proteins 
BL21 DE3 cells expressing the recombinant WT and mutant forms of PRL-3 were 
lysed by sonication in buffer A [50 mM Tris-HCl (pH 7.4) containing 500 mM NaCl, 
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20 mM imidazole, 1 mM dithiothreitol (DTT), and 0.5 mM protease inhibitor 
cocktail]. The proteins were purified using a FPLC Histrap HP 1 mL column using an 
elution gradient from 20 to 500 mM imidazole in buffer A. The purified PRL-3 
proteins were dialyzed against 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM DTT, 
and 10% glycerol. BL21 DE3 cells expressing the recombinant His-PTP1B were 
lysed by sonication in lysis buffer [20 mM Tris-HCl (pH 8.0) containing 150 mM 
NaCl, 10 mM imidazole, 1 mM DTT, and 0.5 mM phenylmethanesulfonyl fluoride 
(PMSF)]. The protein was purified using a FPLC Histrap HP 1 mL column using an 
elution gradient from 10 to 500 mM imidazole in buffer A. BL21 DE3 cells 
expressing recombinant GST−PTEN fusion protein were lysed in 50 mM Tris-HCl 
(pH 8.0), 250 mM NaCl, and 0.5 mM protease inhibitor cocktail. The cell lysate was 
applied to a FPLC GSTrap FF 1 mL column; the column was washed with 50 mM 
Tris-HCl (pH 8.0) and 50 mM NaCl, and then the GST−PTEN fusion protein was 
eluted with 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, and 10 mM glutathione. Purified 
GST−PTEN fusion protein was dialyzed against 50 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, and 1 mM DTT. BL21 DE3 cells overexpressing the pBADM-30-GST-5-ptase 
were lysed in 50 mM sodium phosphate (pH 6.8), 200 mM NaCl, 2 mM DTT, 0.1 
mg/mL lysozyme, and 0.5 mM protease inhibitor cocktail, using a French press, with 
four passes. The cell lysate was applied to a FPLC GSTrap FF 1 mL column, and the 
column was washed with 50 mM sodium phosphate (pH 6.8), 50 mM NaCl, 2 mM 
DTT, and 0.5 mM protease inhibitor cocktail. Then the GST−5-ptase fusion protein 
was eluted with 50 mM sodium phosphate (pH 6.8), 50 mM NaCl, 2 mM DTT, and 
10 mM glutathione. The integrity of all proteins was confirmed by molecular weight 
determination by electrospray ionization mass spectroscopy (ESI-MS). 
 
III.3.5. Peptide Synthesis 
Peptides were synthesized on solid phase Rink amide resin by standard coupling and 
Fmoc protection strategies using an automated MultiSynTech peptide synthesizer. 
Peptides were isolated after cleavage from resin and deprotection using 95 vol % 
trifluoroacetic acid and 5 vol % triisopropylsilane. The peptides were ether-
precipitated and purified to homogeneity (>90% purity) using high-performance 
liquid chromatography, and identities were confirmed by ESI-MS. 
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III.3.6. Far-UV Circular Dichroism (CD) 
WT PRL-3 and mutant variants were dialyzed into 20 mM Tris-HCl (pH 7.4), 50 mM 
NaCl, and 1 mM DTT. Protein concentrations after dialysis were determined by 
absorption at 280 nm using a NanoDrop spectrophotometer. The concentrations used 
in the CD measurements were 0.48 mg/mL for WT PRL-3, 0.43 mg/ mL for the 
D72A mutant, 0.64 mg/mL for the A111S mutant, and 0.6 mg/mL for the C104S 
mutant. Far-UV CD spectra were recorded using a Jasco J-715 spectropolarimeter. 
The spectropolarimeter was purged with N2 for 15 min prior to measurement. CD was 
measured over the far-UV range (195− 250 nm) at 20 °C using a path length of 0.1 
cm. The scan speed was set to 10 nm/min with a wavelength interval of 1 nm. Four or 
five scans were acquired and automatically averaged. The far-UV signal over the 
entire range was initially measured using a buffer sample in the absence of enzyme to 
determine the baseline for subsequent CD spectra. Far-UV CD spectra were acquired 
for WT PRL-3 and for the variants in duplicate. The spectra were then averaged and 
buffer subtracted as well as normalized to a protein concentration of 1 mg/mL. The 
thermal stability of the PRL-3 proteins was also compared by monitoring the CD 
signal at 223 nm as a function of temperature over a range of 20−85 °C with intervals 
of 0.2 °C. The sample was cooled in the spectropolarimeter, and observation of the 
CD signal upon cooling showed that the thermal denaturation of WT PRL-3 and the 
variants was irreversible. Therefore, thermodynamic parameters could not be 
quantitatively determined from the CD data. The midpoint of the thermal denaturation 
curve was estimated and used as a qualitative comparison of the stability of the 
different proteins. 
 
III.3.7. Phosphatase Activity Assays 
A standard enzymatic activity assay was conducted using 3-O-methylfluorescein 
phosphate (OMFP) as a substrate. The assay was conducted at 37 °C in 40 mM Tris-
HCl (pH 6.2), 150 mM NaCl, and 4 mM DTT. WT PRL-3 and mutant variants were 
assayed at 6 µM. OMFP was used at 600 µM in all reactions. The assay was 
conducted in 96-well plate format and monitored by absorbance at 450 nm over time. 
The release of phosphate from candidate peptide and lipid substrates was monitored 
using a commercially available phosphatase assay kit, EnzChek, according to the 
manufacturer's instructions. WT PRL-3 and mutant variants [2 µM, 4.5 µM (for 
phosphopeptide activity assays), or 6 µM (for PIP activity assays)] were incubated 
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with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM MgCl2, and 4 mM DTT in 96-
well plates with either 100 µM phosphopeptide or 100 µM phosphoinositide 
substrates. The assay was conducted at 37 °C with shaking in a Tecan Safire TM plate 
reader. The release of phosphate from the candidate substrates was continually 
monitored by measuring absorbance at 360 nm. For the controls, 52 nM PTP1B was 
incubated with 50 µM phosphopeptide substrate, and 0.9 µM PTEN and 5.8 µM 5-
ptase were incubated with 100 µM phosphoinositide in the same buffer used for the 
PRL-3 measurements. Assays conducted in the absence of enzyme were included in 
the 96-well plate setup in triplicate for all the substrates analyzed. The measurements 
in the absence of enzyme were averaged and subtracted from the data to account for 
nonspecific hydrolysis of the substrates and for background absorption. The data were 
normalized toward the signal of PI(3,4,5)P3 in the no enzyme control to account for 
potential difference due to the use of multiple plates. In all phosphatase assays, the 
measurements were taken in triplicate and the standard deviation of the measurements 
is represented as error bars. Data were plotted using SigmaPlot11. 
Dephosphorylation assays of fluorescently labeled PIPs (Echelon Biosciences) were 
conducted using recombinant PRL-3 (4.5 or 9 µg) in 20 µL of reaction buffer 
containing 50 mM MES (pH 6.5) and 1 mM TCEP [tris(2-carboxyethyl)-phosphine] 
with 1.0 µg of fluorescent di-C6-NBD6 or fluorescent di-C6-BODIPY 
phosphoinositide substrates for 1 h at 37 °C. Phosphatase assays using recombinant 
PTEN were conducted in 20 µL of reaction buffer containing 50 mM ammonium 
carbonate (pH 8.0) in the presence of 1 mM TCEP. Phosphatase assays using 
recombinant 5-ptase were conducted in 20 µL of reaction buffer containing 50 mM 
Tris-HCl (pH 7.5), 50 mM NaCl, and 3 mM MgCl2. Phosphatase reactions were 
terminated by addition of 100 µL of acetone and then mixtures evaporated to dryness 
in a Speed-Vac evaporator. The dried reaction products were resuspended in 20 µL of 
a methanol/chloroform mixture (1/1) and spotted onto a glass-backed TLC plate 
(HPTLC Silica gel 60, 10 cm × 10 cm, Merck).25 The TLC plate was developed in a 
chloroform/ acetone/methanol/glacial acetic acid/water solvent system 
(80/30/26/24/14) as described previously and air-dried.25 Fluorescent lipids were 
visualized using a model FLA 7000 Fuji Bio-Imaging System. 
Phosphatase assays using immunoprecipitated FLAG-tagged PRL-3 wild-type, 
C104S, D72A, or A111S proteins were conducted by incubating resin-bound proteins 
for 1 h at 37 °C in 30 µL of reaction buffer (above) containing 1 µg of di-C6-NBD6-
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phosphatidylinositol 4,5-diphosphate. The samples were then centrifuged for 30 s to 
pellet the beads, and 20 µL of supernatant was removed. Acetone (100 µL) was added 
to each supernatant, and the samples were dried and analyzed as described above. 
 
III.3.8. Molecular Modeling 
The PRL-3 structure in the “closed” active conformation was obtained via homology 
modeling using the crystal structure of PRL-1 (C104S) in complex with a sulfate ion 
(PDB entry 1XM2)26 as a template. Homologue proteins of human PRL-3 were 
identified from UniProt,27 and ClustalW228 was used for multiple-sequence 
alignment. The alignment result between PRL-3 (Q75365) and PDB entry 1XM2 
coincides with those in previous studies.26,29 MODELER (Release 9v8)30 was then 
used for homology modeling. The sulfate ion was kept in the active site during model 
generation. Eleven models were generated, and the best model was selected by three 
criteria: “normalized DOPE score” (MODELER), “dfire_energy” (DFire),31 and 
“model quality score” (ModFOLD).32 This model was further refined by MD 
simulation using NAMD (version 2.7b4)33 with an Amber force field. The charges 
and force field parameters of the sulfate ion were obtained using the Antechamber34 
module in AMBER-Tools (version 1.4), where the charge models were calculated via 
the AM1-BCC method. Atoms on PRL-3 were assigned the parameters of the ff03 
force field. The PRL-3−sulfate complex was soaked in a box of TIP3P35 water 
molecules with a margin of 10 Å along each dimension. Chloride ions were added to 
neutralize the whole system. The system was first minimized with restraints of 5.0 
kcal/mol on protein and sulfate ion for 5000 steps. The time step size was set to 2 fs. 
Then, the system was further minimized without constraints for 15000 steps. After 
that, a 62 ps simulation was used to gradually increase the temperature of the system 
from 0 to 310 K. A subsequent 500 ps simulation was performed to equilibrium under 
a constant temperature of 310 K and a constant pressure of 1 atm. The nonbonded 
cutoff distance was set to 12 Å. During the entire MD simulation, Cys-104 was 
treated as the deprotonated form while Asp-72 was treated as the protonated form. 
The last snapshot of the MD simulation was selected as the final PRL-3 model. 
The three-dimensional (3D) structural model of diC8-PI(4,5)P2 (the deprotonated 
form) was built on the basis of PI(3)P, which was extracted from PDB entry 1ZSQ.36 
It was further optimized via OpenBabel (version 2.2.3)37 using the MMFF94 force 
field. GOLD (version 5.0.1, CCDC Software)38 was then used in molecular docking 
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of diC8-PI(4,5)P2 to the PRL-3 model. GoldScore was selected as fitness function and 
automatic (ligand-dependent) genetic algorithm parameter settings were used with the 
search efficiency set to 100%. The active site residues Arg-6, Asp-72, Val-105, Leu-
108, Arg-110, and Arg-138 were treated as flexible during docking. For the 
constrained docking study, the 4- or 5-phosphate group of diC8-PI(4,5)P2 was 
constrained to point into the catalytic site during docking by setting the constraints for 
the H−O distance between Asp-72 COOH and O-PO3-diC8-PI(4,5)P2 (1.6−2.0 Å) 
and the S−P distance between Cys-104 S and P-O4-diC8-PI(4,5)P2 (3.0−3.8 Å). 
 
III.3.9. Generation of Cell Lines Stably Expressing PRL-3 Variants 
The Flp-In 293 T-Rex (tetracycline-regulated system) cell line (Invitrogen) was used 
to create isogenic cell lines stably expressing wild-type and mutant PRL-3 proteins 
with N-terminal FLAG epitope tags. Cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 1% glutamine, 1% 
penicillin/streptomycin, 10% fetal bovine serum (FBS) (Invitrogen), 15 µg/mL of 
blasticidin, and 100 µg/mL hygromicin. The expression of the PRL-3 proteins was 
induced by addition of 1 µg/mL tetracycline to the growth medium. 
 
III.3.10. Western Blot 
Cell lysates were subjected to sodium dodecyl sulfate−polyacrylamide gel 
electrophoresis (SDS− PAGE) and immunoblot analysis with antibodies against 
FLAG (Sigma) and β-actin (Sigma). 
 
III.3.11. Indirect Immunofluorescence 
To visualize FLAG-tagged PRL-3, HEK293 cells stably expressing either WT PRL-3 
or mutants were seeded onto LabTek eight-well chamber slides (NUNC) precoated 
with polylysine. Cells were fixed with 4% paraformaldehyde for 15 min at room 
temperature, permeabilized with 0.1% Triton X-100 and phosphate-buffered saline for 
10 min, and blocked with 1% bovine serum albumin for 1 h. The anti-FLAG antibody 
was then added to the cells, followed by the Alexa Fluor 488 goat anti-mouse IgG 
secondary antibody (Invitrogen). After being washed with phosphate-buffered saline, 
cells were incubated with Hoechst 33342 (2 µg/mL) for 5 min and imaged using a 
Leica SP2 sirius confocal microscope system. 
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III.3.12. Wound Healing Motility Assays 
Cell migration assays were conducted using µ-Dish 35 mm Culture Inserts (Ibidi) 
according to the manufacturer’s protocols. In brief, cells stably expressing either 
PRL-3 wild-type, mutants, or an empty vector were seeded into each well of the 
culture inserts in the presence of tetracycline and incubated at 37 °C in a humidified 
atmosphere with 5% CO2. On the day of experimentation, the culture inserts were 
gently removed by using sterile tweezers, and the dish was filled with fresh DMEM 
supplemented with 5% FBS. Photos of the wound were taken under a Zeiss 
Cellobserver HS microscope (10× magnitude). 
 
III.3.13. Immunoprecipitation of PRL-3 Proteins 
Cells stably expressing PRL-3 proteins were grown in the presence of tetracycline. 
Cells were lysed on ice in a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1 mM EDTA, and Complete Protease Inhibitor (Roche) by being passed 
through 26-gauge needles 10 times. Lysates were cleared by centrifugation (10 min at 
18000g and 4 °C), and the supernatants were incubated on a rocker for 2 h at 4 °C 
with 40 µL of anti-FLAG M2-agarose affinity resin (Sigma). Samples were washed 
three times with lysis buffer followed by an additional wash with the phosphatase 
reaction buffer (see above). 
 
III.4. Results and discussion 
III.4.1. Characterization of the PRL-3 Variants 
To characterize the in vitro phosphatase activity of PRL-3, we analyzed wild-type 
(WT) PRL-3 and three key variants, C104S, D72A, and A111S PRL-3. Mutation of 
the essential active site Cys 104 to Ser inactivates PRL-3 phosphatase activity.10 In 
the D72A mutant, the activity of PRL-3 is also affected by the disruption of the acidic 
loop that is required for hydrolysis of a substrate once it is bound to the active site, 
and the mutant has been reported to be catalytically inactive, at least toward OMFP.21 
With regard to the A111S mutant, an active site Ser residue is a conserved feature 
among many DSPs and is implicated in the catalytic mechanism. Such a Ser is not 
featured in the PRL family of DSPs, possibly explaining the much weaker in vitro 
activity of PRLs relative to those of other DSPs. The variant of PRL-3 in which Ala 
111 has been substituted with Ser has been reported to be hyperactive toward 
OMFP.21 The phosphatase activity of the proteins was initially compared using 
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OMFP as a substrate21 (Figure III.2). Consistent with a previous report,21 WT PRL-3 
exhibits very weak activity toward OMFP, D72A PRL-3 shows no significant 
dephosphorylation of OMFP, and the A111S mutant exhibits considerably higher 
activity than WT PRL-3. Mutation of the essential active site Cys 104 to Ser 
inactivates PRL-3 phosphatase activity. 
 
 
 
Figure III.2. Hydrolysis of OMFP (600 µM) by wild-type PRL-3 and mutant forms of 
PRL-3: A111S, D72A, and C104S (6 µM each). Measurements were taken in 
triplicate, and the standard deviation of the measurements is represented as error 
bars. 
 
To further characterize WT PRL-3 and its variants, far-UV circular dichroism (CD) 
spectra were acquired.22 The CD measurements show significant structural changes 
for the A111S and C104S mutants compared to WT PRL-3, whereas D72A exhibited 
much less structural perturbation (Figure III.3A). The CD signal was then monitored 
at increasing temperatures to compare the thermal stability of the PRL-3 variants. The 
apparent melting temperatures of C104S (52 ± 2 °C) and A111S (51 ± 2 °C) are 
significantly lower than that of WT PRL-3 (62 ± 2 °C), while the melting temperature 
of D72A appears to be higher [>65 °C (Figure III.3B−E)]. These results suggest that 
the mutations within the catalytic region of PRL-3, i.e., the A111S and C104S 
mutations, have a more significant impact on the structural stability of PRL-3 than a 
mutation in a distant region (D72A). In both destabilized variants, a hydrophilic 
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residue is introduced into the hydrophobic p-loop of PRL-3.39 This could also 
contribute to the structural destabilization. 
 
 
 
Figure III.3. Secondary structure analysis of the PRL-3 variants by far-UV CD. (A) 
Far-UV CD spectra of WT PRL-3 as well as the D72A, C104S, and A111S mutants. 
(B−E) Thermal stability curves of WT PRL-3 (B), D72A PRL-3 (C), A111S PRL-3 
(D), and C104S PRL-3 (E). For experimental details, see  Materials and Methods 
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III.4.2. Determination of the Catalytic Activity and Specificity of WT PRL-3 and 
Its Variants 
The phosphatase activity of WT PRL-3 and A111S PRL-3 toward phosphorylated 
peptide substrates was then analyzed. The A111S mutant was used because of its 
enhanced activity toward OMFP and thus potential higher sensitivity. The 
phosphatase concentrations were chosen to be in the low micromolar range, and thus 
quite high, because of the reported low activity of PRL-3 toward peptides and OMFP 
in vitro,21 and for the same reason, a high peptide concentration was selected (100 
µM). A commercially available dephosphorylation assay (EnzChek) was used to 
monitor the release of phosphate continuously over time (Figure III.4, data at 30 min). 
The peptide substrates [peptides 1−6 (Table  1)] were designed on the basis of 
proteins reported to be affected by PRL-3 and thus potentially interact with PRL-3 in 
vivo.7,10,11,13,14,16−18 Three more peptides [peptides 7−9 (Table  1)] were included to 
increase the variety of amino acid properties and peptide length. 
 
Table 1. Sequence Features and Origins of the Phosphorylated Peptides Used as 
Substrates for in Vitro Dephosphorylation Assays 
 
 
aNH2 is the C-terminal amide; Ac is the N-terminal acetyl group, and biotin denotes 
N-terminal biotinylation. bUniProt data. cFrom refs  10 and  11 
 
Neither WT PRL-3 nor A111S PRL-3 dephosphorylates any of our peptide 
substrates significantly (Figure III.4). As a positive control, dephosphorylation of 
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peptides by the Tyr-specific phosphatase PTP1B40 was monitored in parallel with 
PRL-3. PTP1B shows a high degree of phosphatase activity toward phosphotyrosine 
peptides. Because of the potential further application of the peptides, they were either 
biotinylated or acetylated. Comparison between peptides 1 and 2 shows that the 
addition of either group has no effect on PRL-3 phosphatase activity. The lack of in 
vitro activity of PRL-3 toward phosphopeptides could indicate that PRL-3 needs a 
cofactor or post-translational modification to be able to dephosphorylate proteins, or 
that it requires the entire protein for recognition as a substrate. On the other hand, 
other DSPs such as CDC25 and MKP3 have also been reported to have weak activity 
toward peptides derived from protein substrates;41,42 thus, the lack of in vitro activity 
is not necessarily unusual. 
 
 
 
Figure III.4. Dephosphorylation of phosphopeptides by WT PRL-3 (4 µM, black), 
A111S PRL-3 (4 µM, light gray), and PTP1B (52 nM, dark gray). Phosphopeptides 
were assayed at 100 µM for PRL-3 variants and at 50 µM for PTP1B. Phosphate 
release was measured in triplicate using the EnzChek assay (see  Materials and 
Methods). The averaged data are shown, and the standard deviation is represented as 
error bars. Absorption intensities of <0.05 au are considered to be not significant 
because of combined spectral and manual error. 
 
PRL-3 is structurally similar with the lipid phosphatase PTEN (Figure III.1), and it 
carries a C-terminal CAAX box, which not only is featured in known lipid 
phosphatases but also localizes PRL-3 to the cellular compartments rich in 
phosphoinositides (PIPs). In addition, certain PIPs such as PI(3,4,5)P3 and PI(3,4)P 2 
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and also depletion of PI(4,5)P2 have been described as being involved in promoting 
cell motility, and these roles have been shown to be important in cancer.43 Thus, 
further investigations were conducted using PIPs as lipid substrates. The release of 
phosphate from soluble PIP substrates carrying dioctanoyl (diC8) lipid chains by WT, 
C104S, D72A, and A111S PRL-3 as well as PTEN and type IV 5-phosphatase (5-
ptase) was continuously measured over 2 h using the EnzChek assay. 5-ptase does not 
belong to the PTP superfamily and uses a catalytic mechanism diﬀerent from that of 
PTPs; however, it has been reported to dephosphorylate PI(4,5)P2 and PI(3,4,5)P3 44 
and was therefore used here as a second control. The signal intensity after 
dephosphorylation for 30 min was used to compare the substrate preferences of each 
individual enzyme against the whole range of phosphoinositides. The resulting 
substrate preference profiles are shown in Figure III.5A. 
As expected, PTEN dephosphorylates PI(3,4,5)P3 and shows no significant activity 
toward the other PIPs (Figure III.5A). Also as expected, 5-ptase removes phosphate 
preferentially from PI(4,5)P2 and PI(3,4,5)P3, demonstrating the robustness of the 
assay. WT PRL-3 exhibits lipid phosphatase activity toward PI(4,5)P2 and, to a lesser 
extent, toward PI(3,4,5)P 3, with no significant activity measured against the other PIP 
substrates. D72A PRL-3 shows weakened lipid phosphatase activity but with the 
same substrate preferences as WT PRL3. The C104S and, surprisingly, A111S 
variants exhibit no lipid phosphatase activity toward any of the measured 
phosphoinositide substrates. 
By comparison of the substrate preference profiles of all the phosphatases assayed 
here (Figure III.5A), it is clear that WT PRL-3 and the less active D72A variant show 
substrate preferences very similar to those of 5-ptase, rather than those of PTEN. 
Although the substrate preferences of PRL-3 match those of the 5-ptase and partially 
match those of PTEN, there are significant differences in the kinetics of 
dephosphorylation for each of these enzymes. Dephosphorylation of PI(3,4,5)P3 by 
PRL-3 compared to that by PTEN and 5-ptase is shown in Figure III.5B. In spite of 
the lower concentration used in our assay, PTEN is more active than PRL-3 toward 
PI(3,4,5)P3. The 5-ptase, assayed here at high concentrations like those of PRL-3, also 
has faster activity against PI(3,4,5)P3 than PRL-3. The dephosphorylation of PI(4,5)P2 
by PRL-3 and 5-ptase is compared in Figure III.5C. These kinetic traces clearly show 
that 5-ptase demonstrates faster reaction kinetics toward PI(4,5)P2 than PRL-3. 
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Figure III.5. Dephosphorylation of PIPs by WT PRL-3 and its variants (6 µM), 
PTEN (0.9 µM), and type IV 5-phosphatase (5.8 µM). The full range of 
phosphoinositide substrates was analyzed at 100 µM. (A) The absorption at 360 nm 
after dephosphorylation of each substrate for 30 min shows the substrate preference 
profiles for each enzyme. (B and C) Kinetic traces of dephosphorylation of (B) 
PI(3,4,5)P3 by WT PRL-3, PTEN, and type IV 5-phosphatase and (C) PI(4,5)P2 by 
WT PRL-3 and type IV 5-phosphatase. Measurements were taken in triplicate and 
individually corrected for background by subtracting the absorbance from a 
corresponding PIP sample incubated in the absence of enzyme. The background-
corrected absorbance was then normalized to the signal of the PI(3,4,5)P3 control 
without enzyme and averaged. The standard deviation of the averaged normalized 
data is represented as error bars. Absorption intensities below 0.30 au (resulting 
from normalization of the original value of 0.05 au and averaging) are considered to 
be not significant because of the combined spectral and manual error. 
 
 52 
The D72A and A111S PRL-3 variants show discrepancies between their activities 
toward OMFP and toward PIPs. The D72A variant has no activity against OMFP but 
does have attenuated wild-type-like activity toward the PIP substrates (Figures III.2 
and III.5A). This could be simply due to enhanced sensitivity to the PIPs as potential 
natural substrates compared to the unnatural OMFP substrate, or because of the 
apparent overall structural stabilization of the mutant as indicated by our CD studies. 
In addition, D to A mutant PTPs have been reported to be able to sustain some 
catalytic activity, presuming another residue in the protein can substitute the missing 
general acid required for the catalytic mechanism.45 Within the active site of PTPs, 
there is a conserved Ser/Thr that could fulfill this role.45 However, there is no such 
equivalent residue in the active site of PRL-3 (A111), indicating that the general acid 
property needs to be provided by another residue within the protein or from the 
substrate itself. The highly negatively charged PIPs as substrates for PRL-3 could 
quite feasibly compensate for the loss of acid in the mechanism of dephosphorylation 
by the D72A mutant. The A111S PRL-3 variant has been shown to be a hyperactive 
form of the protein toward OMFP21 (Figure III.2), yet this mutant does not 
dephosphorylate any PIP substrates in our in vitro assays (Figure  III.5A). Given that 
our CD studies show perturbations in the structure of A111S PRL-3 relative to that of 
the wild-type protein, this Ala residue could play an important role in maintaining the 
integrity of the active site. However, on the basis of our current data, we cannot 
determine unequivocally whether the inactivity of A111S PRL-3 and the activity of 
D72A PRL-3 toward PIP substrates are due to structural changes relative to the WT 
protein or differences in the enzymatic mechanism. For C104S PRL-3, the lipid 
phosphatase activity is consistent with the OMFP activity assays, which demonstrates 
that replacing Cys 104 with Ser completely inactivates the phosphatase. 
To further validate our findings, we repeated the dephosphorylation assay with 
PI(4,5)P2 and PI(3,4,5)P3 using PIP derivatives that are fluorescently labeled in one 
lipid chain. The dephosphorylation of the substrates was analyzed by thin layer 
chromatography (Figure III6). As seen in Figure III6A, PI(4,5)P2 is dephosphorylated 
by PRL-3 and 5- ptase but not PTEN, confirming the results of the previous assay. 
Dephosphorylation of PI(3,4,5)P3 by WT PRL-3 was not seen in this assay; it was, 
however, dephosphorylated by PTEN and 5-ptase, showing the robustness of this 
assay (Figure III6B). 
It is unclear why PRL-3 lacks PI(3,4,5)P3 phosphatase activity in this assay. We can 
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speculate that the different result could be due to the presence of a different lipid 
chain in the fluorescent PIP; however, this was not represented in the PI(4,5)P2 data. 
Also, the weak in vitro activity of PRL-3 could contribute to this result. Despite such 
discrepancies, we have definitively confirmed PRL-3 phosphatase activity toward 
PI(4,5)P2, and thus, PRL-3 could be the first phosphatase in the PTP superfamily to 
dephosphorylate this PIP. 
 
 
 
Figure III.6. Dephosphorylation of fluorescently labeled PI(4,5)P2 (A) and 
PI(3,4,5)P3 (B) by WT PRL-3, 5-ptase, and PTEN. Phosphatase assays containing 
1.0 µg of fluorescent phosphoinositide substrate were conducted for 1 h at 37 °C with 
buffer (−) or with different concentrations of recombinant proteins (as indicated), 
processed as described in  Materials and Methods, and analyzed by TLC. PI(3,4,5)P3 
dephosphorylation assays were performed under the same conditions using 9 µg of 
recombinant protein. Shown is a representative result of three experiments. 
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We then analyzed the product of PI(4,5)P2 dephosphorylation by PRL-3 by 
comparing the product to the mono-phosphorylated PIPs to determine which 
phosphate on the ring is released by PRL-3. Figure III.7 shows the fluorescence read-
out of the dephosphorylation of PI(4,5)P2, PI(4)P, and PI(5)P by PRL-3. The 
monophosphorylated PIPs run quite close. PI(4)P runs closer to the product of the 
PI(4,5)P2 dephosphorylation by PRL-3, whereas there is a clear gap between the 
product and PI(5)P. This result provides support for PRL-3 being a 
phosphatidylinositol 5-phosphatase. 
 
 
 
Figure III.7. Dephosphorylation of fluorescently labeled PI(4,5)P2, PI(5)P, and 
PI(4)P by WT PRL-3. Phosphatase assays containing 1.0 µg of fluorescent 
phosphoinositide substrate were conducted for 1 h at 37 °C with 9 µg of recombinant 
PRL-3 or in the presence of buffer only. Shown is a representative result of three 
experiments. 
 
Further, molecular modeling of PRL-3 with diC8-PI(4,5)P2 can support the 
feasibility of PRL-3's 5-phosphatase activity. The aim of our model study was to find 
the highest-scoring docking solution containing either the 4- or the 5-phosphate 
pointing toward the catalytically active Cys. Because there is no structure available 
for PRL-3 bound to a ligand, we performed homology modeling and MD simulation 
for model refinement using the structure of PRL-1 bound to a sulfate ion (PDB entry 
1XM2) as a template.26 The 3D structural model of diC8-PI(4,5)P2 in the 
deprotonated form for molecular docking was built on the basis of the structure of 
PI(3)P bound to MTMR2.36 During the entire process, Cys 104 was considered to be 
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deprotonated and hence functions as a nucleophile in the catalytic reaction. Asp 72 
was considered protonated and therefore able to act as a general acid in catalysis. One 
hundred docking solutions were generated and ranked by GoldScore. To select the 
possible binding mode, the complex structures of MTMR2 with PI(3)P (PDB entry 
1ZSQ) and PI(3,5)P2 (PDB entry 1ZVR)36 were used for reference. A common 
feature of the binding mode in these two structures is that the hydrogen on the carbon 
atom that carries the phospho group pointing into the catalytic site is opposite to the 
“general acid” residue Asp 422. The highest-scoring docking solution satisfying this 
feature was selected as the initial predicted binding mode (Figure III.8A,B). In this 
docking solution, the 5-phosphate of diC8-PI(4,5)P2 is dephosphorylated. To further 
test this preference, a constrained docking study was performed in which either the 4- 
or 5-phosphate was constrained in the catalytic pocket. Three parallel dockings were 
performed for each situation, and 10 docking solutions were generated in each run. 
Solutions satisfying the feature described above with the highest score in each run 
were selected for comparison. The results show that the scores for docking solutions 
in which the 5-phosphate points into the catalytic site are generally higher. The 
highest-scoring one, which also scores higher than the initial predicted binding mode, 
was selected as the final predicted binding mode (Figure III.8C,D). These theoretical 
studies further corroborate the hypothesis that PRL-3 could be a phosphatidylinositol 
5-phosphatase. 
 
III.4.3. Investigation of the Influence of the Mutations on PRL-3's Ability To 
Promote Cell Migration 
Next, we determined the cellular phenotype of WT PRL-3 and its variants. PRL-3-
overexpressing cells are reported to enhance cell migration in a wound healing 
assay.3,17 Thus, we created stable cell lines of all PRL-3 variants as well as WT PRL-3 
and a stable control cell line with the empty vector using the Flp-In 293 T-Rex cell 
line (Invitrogen). All PRL-3 proteins were triple FLAG-tagged at the N-terminus. 
Anti-FLAG Western blot analysis showed that all PRL-3 cell lines express the 
proteins in equal amounts (Figure III.9A), and immunofluorescence read-out with 
anti-FLAG antibodies shows that in all cell lines the proteins are localized equally to 
the plasma membrane as expected (shown for WT PRL-3 in Figure III.9B, data of the 
variants not shown). There was no expression of PRL-3 observed in the control cell 
line. 
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Figure III.8. Docking solution of PI(4,5)P2 bound to PRL-3. (A) Initial predicted 
binding mode. (B) Close-up of the catalytically active site of the structure in panel A. 
The 5-phosphate points toward Cys 104. (C) Final predicted binding mode, with the 
solution with the highest score. (D) Close-up of the catalytically active site of the 
structure in panel C. 
 
 
 
Figure III.9. Generation of stable Flp-In T-Rex 293 cells expressing FLAG-tagged 
WT PRL-3 or its mutants under the control of a tetracycline inducible promoter. 
(A) Western blot (WB) analysis of cell lysates from stable cell lines expressing WT or 
mutant PRL-3. Cells were incubated overnight in medium containing 1 µg/mL 
tetracycline, harvested, lysed, and probed with an anti-FLAG antibody to assess the 
expression levels; an anti-β-actin antibody was used as a loading control. A control 
cell line was also generated by transfecting Flp-In 293 cells with the blank vector 
(Ctrl). (B) The stable cell lines were processed for indirect immunofluorescence using 
the FLAG antibody (left). Hoechst was used to stain the nuclei (right). Only WT PRL-
3 is shown. 
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We then conducted wound healing assays with all cell lines (Figure III.10). As 
expected, the WT PRL-3 cell line closes the wound faster than the empty vector 
control cell line, demonstrating that WT PRL-3 promotes cell migration. The 
phenotype of the C104S PRL-3 cell line is the same as that of the empty vector 
control cell line, which is in agreement with the fact that the C104S mutant is inactive 
in vitro, and it also agrees with reports in the literature.3,46 This indicates that PRL-3 
catalytic activity is required to promote cell migration. The D72A PRL-3 cell line 
exhibited the same phenotype as WT PRL-3 cells. This correlates with the residual 
lipid phosphatase activity detected for this variant (see above). As discussed above, 
the D to A mutation does not completely inactivate the phosphatase, and given that 
D72A PRL-3 is highly over-expressed in our system, the residual catalytic activity of 
this variant could be sufficient for promoting cell migration. Fiordalisi et al. reported 
the same observation using stably transfected SW480 cells.17 In another report, D72A 
PRL-3 transiently transfected into mouse B16 cells showed that the extent of 
promotion of cell migration in a Transwell assay was greatly reduced. However, some 
residual activity was observed compared to that of the C104S mutant and mock vector 
control.46 
We made an astonishing observation when monitoring the cellular phenotype of the 
A111S mutant: It showed the same lack of activity in accelerating cell migration as 
the empty vector and the C104S mutant cell line. To the best of our knowledge, this 
mutant has never been tested in a wound healing assay. The hyperactivity toward the 
unnatural substrate, OMFP, is thus not apparent in the context of a living cell. On the 
other hand, the inactivity of A111S PRL-3 toward PI(4,5)P2 in our in vitro assays is in 
complete agreement with the observed phenotype. This finding provides evidence that 
the natural S111A mutation in PRL-3 is required for its function, and it might suggest 
that there are unknown mechanisms involved in the catalytic activity of the PRL 
family. It may also be that the A111S mutant no longer recognizes its natural 
substrate, which could potentially be due to structural perturbation in the variant. 
Importantly, our data clearly emphasize the need for caution when relating 
phosphatase activity with unnatural substrates such as OMFP to potential in cell 
activity. 
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Figure III.10. Wound healing assay with stable HEK 293 cell lines expressing WT, 
C104S, D72A, and A111S PRL-3 as well as the empty vector control. Stable cell 
lines were incubated overnight in medium containing 1 µg/mL tetracycline to induce 
PRL-3 protein expression. A cell-free gap of approximately 500 µm was created by 
removing the Culture-Insert. The dishes were filled with fresh DMEM supplemented 
with 5% FBS and 1 µg/mL tetracycline to maintain protein expression. The wounded 
areas were photographed at the beginning of the assay (0 h, top panels) and after 18 
h (18 h, bottom panels). Shown is a representative result of three experiments. 
 
To ensure that the activity of the recombinant protein really correlates with the 
enzyme when it is stably expressed in cells, all four PRL-3 proteins were 
immunoprecipitated and their phosphatase activity was analyzed using the 
fluorescently labeled PI(4,5)P2. Figure III.11 demonstrates that immunoprecipitated 
WT and D72A PRL-3 can dephosphorylate PI(4,5)P2, whereas the C104S and A111S 
variants lack phosphatase activity toward this substrate. These results are in complete 
agreement with the observed activity of the recombinant variants and also correlate 
with the observed phenotypes in wound healing assays. 
Taken together, the monitored cellular phenotypes of all PRL-3 variants in stable 
HEK293 cell lines are in complete agreement with their activity toward PI(4,5)P2 
measured using two completely different biochemical assays. This suggests that this 
activity can be correlated to PRL-3's function in vivo. 
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Figure III.11. Dephosphorylation of fluorescently labeled PI(4,5)P2 using 
immunoprecipitated WT, D72A, C104S, and A111S PRL-3. FLAG-tagged PRL-3 
proteins were purified by immunoprecipitation with anti-FLAG affinity resin from 
HEK293 stable cell lines. Immunoprecipitates were incubated with 1.0 µg of 
fluorescently labeled PI(4,5)P2 for 1 h at 37 °C, processed as described in  Materials 
and Methods, and analyzed by TLC. Shown is a representative result of three 
experiments. Similar PIP background levels as in C104S and A111S PRL-3 lanes are 
also apparent in TLC read-outs using noninduced WT PRL-3 cells for 
immunoprecipitation (data not shown). 
 
III.5. Concluding remarks 
PRL-3 overexpression affects the regulation of multiple proteins and pathways 
leading to several favorable conditions for cancer progression and invasiveness.2 
Intriguingly, PI(4,5)P2 plays a role upstream of many of the described signaling 
networks in which overexpressed PRL-3 exerts its activity. PI(4,5)P2 is an important 
modulator of cytoskeleton organization during diverse cellular functions such as focal 
adhesion formation and cell migration. These dynamic processes require rapid and 
highly localized changes in PI(4,5)P2 content; therefore, PI(4,5)P2 levels are spatially 
and temporally regulated by the action of PI(4)P 5-kinases, 5-phosphatases, and 
phospholipase C enzymes (PLC).43,47,48 Sequestration or depletion of membrane 
PI(4,5)P2 decreases the plasma membrane− cytoskeletal adhesion energy leading to 
changes in cell shape, reduction of cell−substrate adhesion, and formation of blebs.49 
Moreover, reduction of PI(4,5)P2 levels through either hydrolysis by PLCγ or 
impairment of the PI(4,5)P2-producing kinase PIPKIγ has been described as playing a 
role in cancer.43 Depletion of PIPKIγ leads to a morphological transformation from an 
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epithelial to a mesenchymal phenotype.50 Reduction of PI(4,5)P2 levels by PLCγ 
activates Cofilin-mediated enhanced cell motility.43,48 Thus hypothetically, the role of 
PRL-3 in cancer metastasis and progression could be mediated via an effect on 
PI(4,5)P2 levels. 
PRL-3 is suggested to reduce the number of focal adhesions and/or increase the rate 
of focal adhesion turnover in cells leading to enhanced cell migration.2 Focal 
adhesions are sites where cellular contact with the extracellular matrix is mediated by 
Integrins, and focal adhesion complexes contain more than 150 components.43 Levels 
of PI(4,5)P2 at the cell membrane are crucial for regulating the dynamics of focal 
adhesion complexes.43 A key component of focal adhesion complexes is focal 
adhesion kinase (FAK), which integrates external signals to promote cell motility via 
many different pathways involving the regulation of or interaction with proteins such 
as Cadherins, Src, p130Cas, Rho-family GTPases, and Ezrin,51 many of which have 
been implicated as being affected by or interacting with PRL-3.1,2,10,11,13,14,16−18,20 
Therefore, our finding that PRL-3 is active toward PI(4,5)P2 offers a reasonable link 
to described effects of PRL-3 overexpression. 
Little is known regarding the physiological role of PRL-3. If PRL-3 is a 
phosphatidylinositol 5-phosphatase, it would have to be tightly regulated in healthy 
cells given the importance of its potential substrate PI(4,5)P2. PRL-3 is expressed 
only in low levels in specific tissues (skeletal muscle and heart),1,2 which could be a 
hint about it being tightly regulated. In addition, its tight regulation has been 
described in the context of a nuclear function.52 PIPs exist in the nucleus and regulate 
a number of processes such as chromatin remodeling and DNA repair; however, only 
one 5-phosphatase (SHIP2) has been reported in the nucleus, and its function is 
unclear.6 In general, 10 human 5-phosphatases have been discovered to date, but none 
of them belongs to the superfamily of PTPs.6 They conduct a variety of different 
functions and are regulated and expressed distinctly; however, our knowledge of 
regulatory mechanisms is in general still limited.6,43 Alterations in these phosphatases 
lead to a number of diseases.6,43 Their roles in cancer are very diverse and 
controversial, and they can range from tumor suppressors to cancer-promoting 
proteins, which was generally investigated in relation to their ability to 
dephosphorylate PI(3,4,5)P3 to PI(3,4)P2.43 
These considerations make our hypothesis that PRL-3 could be a 
phosphatidylinositol 5-phosphatase very reasonable. Currently, we are working on the 
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proof that PRL-3 has in vivo lipid phosphatase activity. Our results offer a new view 
of PRL-3's function and role and open up new lines of investigation for this important 
oncogene. 
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Chapter IV: The Metastasis-Promoting Phosphatase PRL-3 affects 
epithelial cell polarization by altering post-mitotic midbody fate 
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IV.1. Abstract 
Epithelial organs are typically organized in elongated tubules and lumen-containing 
spherical cysts. Apical cell polarity specification and coordinated lumen formation 
require a complex crosstalk between the trafficking machinery and polarity complex 
proteins. Here we show that over-expression of the metastasis-associated phosphatase 
PRL-3 significantly affects epithelial morphogenesis by interfering with the fate of 
post-mitotic midbodies. We identified the post-mitotic midbody as the first 
polarization signal during cyst development, defining the apical domain and the 
lumen position. PRL-3 over-expression promotes intracellular as well as lateral 
plasma membrane retention of post-mitotic midbodies, generating cysts with ectopic 
lumens that arise at the sites where post-mitotic midbodies are retained. These results 
define a critical function of post-mitotic midbodies in the establishment and 
maintenance of the axis of polarity, reveal that PRL-3 can regulate post-mitotic 
midbody fate and show that PRL-3 aberrant expression is associated with major 
defects in epithelial cell polarization, suggesting a novel mechanism for epithelial 
tumorigenesis. 
 
IV.2. Introduction 
Polarized epithelial cells are characterized by the asymmetric distribution of both 
proteins and lipids across the plasma membrane1. This asymmetry is required to 
generate apico-basal polarity1,2. The process of epithelial polarization and de novo 
lumen formation has been extensively studied in the three dimensional (3D) MDCK 
cell system, an excellent in vitro model of epithelial morphogenesis3,4. MDCK cells, 
in contact with extracellular matrix, form polarized lumen-enclosing spherical cysts 
with the apical membrane facing a hollow central lumen and a basal surface attached 
to a layer of extracellular matrix. Recently, important insights into the early stages of 
lumenogenesis have been described 3,5,6. De Novo lumen formation in MDCK cysts 
requires polarized exocytosis of membrane vesicles at specific sites of cell-cell 
contact in the core region of the cysts. This region is specified as a specialized 
membrane domain called the “apical membrane initiation site” (AMIS) and is the site 
where the lumen will open. The polarization process in MDCK cysts starts at a very 
early stage with the selective localization of key polarity and trafficking proteins to 
the AMIS5–7. However, how the AMIS and subsequently the lumen position are 
specified exactly in center of the cysts is still an open question. 
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Epithelial tissue is the source of more than 80% of human cancers such as 
colorectal cancer, and the loss of apico-basal polarity in epithelial cells is considered a 
fundamental event during malignant tumor progression and metastasis8,9. Phosphatase 
of Regenerating Liver-3 (PRL-3) is a metastasis-associated phosphatase and an 
emerging prognostic marker for prediction of human colorectal cancer progression10. 
PRL-3 belongs to the family of Dual Specificity Phosphatases (DSPs), consists only 
of a single domain and carries a C-terminal prenylation motif. The C-terminal lipid 
prenyl group is essential for PRL-3 subcellular localization, anchoring the protein to 
membrane compartments such as the plasma membrane11,12. Although the correlation 
between aberrant PRL-3 expression and the acquisition of a migratory and invasive 
cell phenotype is well established, the molecular basis of PRL-3 function is unclear12. 
Here, we show that the overexpression of PRL-3 in MDCK cysts significantly affects 
epithelial morphogenesis. Moreover, we demonstrate that a remnant of the cytokinesis 
process, the post-mitotic midbody13, defines the position where the AMIS and thus 
the lumen will be positioned. Finally, we demonstrate that PRL-3 overexpression 
affects apical lumen formation in MDCK cysts by promoting intracellular or lateral 
plasma membrane retention of post-mitotic midbodies. In summary, we describe a 
novel role of midbody remnants in cell polarity, identify the metastasis-associated 
phosphatase PRL-3 as a protein involved in the determination of midbody fate and we 
show that this PRL-3 disregulation is associated with major defects in epithelial cell 
polarization in a non-cancerous background. 
 
IV.3. Results 
IV.3.1. PRL-3 overexpression affects the formation of a single apical lumen in 
epithelial cells 
Several reports over the past few years have suggested a correlation between high 
PRL-3 expression and metastatic progression of epithelial cancers10–12 but the effect 
of PRL-3 overexpression on cellular polarity has not been examined11,12. To 
determine if PRL-3 overexpression affects epithelial cell polarity in MDCK cysts, we 
stably expressed the WT version of PRL-3 fused to GFP (GFP-PRL-3 WT) in MDCK 
cells. The resulting cell lines showed a heterogeneous expression of PRL-3 allowing 
us to compare, in the same sample, the effect of PRL-3 in MDCK cystogenesis with 
respect to cells with low or no expression. As previously reported, MDCK cells form 
spherical cysts in Matrigel characterized by a central hollow lumen surrounded by one 
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layer of polarized cells7,14. In these cysts (Fig. IV.1a, arrowhead), F-actin is enriched 
at the apical membrane facing the central lumen15. By contrast, PRL-3 overexpressing 
cysts are frequently abnormal with multiple lumens positive for F-actin (Fig. IV.1a, 
arrows; Fig. IV.1d,f,g). Interestingly, mosaic cysts, where only few cells express 
PRL-3, are also abnormal (Fig. IV.1b), with PRL-3 expressing cells extended from 
the monolayer to the lumenal space. These defects are attributable to PRL-3 catalytic 
activity because MDCK cysts stably expressing the catalytic inactive mutant of PRL-
3 (GFP-PRL-3-C104S) show a normal phenotype comparable to parental cysts15 (Fig. 
IV.1c,e,g). Furthermore, in PRL-3 WT overexpressing cysts intracellular lumen-like 
structures are frequently observed that are not connected with cell-cell contact regions 
(Fig. IV.1d,e arrows). These results suggest that enhanced PRL-3 catalytic activity 
causes the formation of multiple lumens in MDCK cysts. 
 
IV.3.2. PRL-3- induced ectopic lumens preserve key luminal marks 
As reported previously, MDCK cells establish apicobasal polarity at a very early stage 
of cystogenesis when the membranes that face the lumen acquire a clear apical 
identity and well-defined tight junctions are formed5–7. To further characterize PRL-3- 
induced ectopic lumens, we investigated the localization of tight junction proteins and 
apical markers in PRL-3 WT cysts. The tight junction markers ZO-1 and Par3 localize 
to the apical sites of cell-cell contact adjacent to the central lumen in PRL-3 C104S 
cysts (Fig. IV.2a,c) as previously reported for parental cysts5,16. Interestingly, PRL-3- 
induced ectopic lumens are still flanked by tight junctions (Fig. IV.2b,d). Moreover, 
PRL-3 WT cysts are still able to polarize apical markers, generating ectopic lumens 
where key apical surface determinants are maintained. To this end, ectopic lumens are 
PI(4,5)P2 and Annexin2 positive (Fig. IV.S1b,d) like the central lumen in PRL-3 
C104S cysts (Fig. IV.S1a,c and see ref. 16) and enriched in phosphorylated Ezrin 
(Fig. IV.2e,f). Taken together these results indicate that enhanced PRL-3 catalytic 
activity leads to a failure in the specification of the lumen position rather than a 
disruption in overall cell polarity, giving rise to fully polarized lumens in ectopic 
positions. 
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Figure IV.1. PRL-3 overexpressing MDCK cells fail to form normal cysts with an 
integrated single lumen. (a) Representative confocal microscopy images of cysts 
expressing GFP-PRL-3 WT (green) at 72-96 h after plating and incubated with 
Hoechst (blue) to visualize nuclei and with phalloidin (red) to visualize actin. 
Arrowheads indicate parental MDCK cyst, arrows indicate GFP-PRL-3 WT 
overexpressing cysts. (b) Representative confocal microscopy images of hybrid cysts 
formed by parental and PRL-3 WT overexpressing MDCK cells, stained as in a. (c-f) 
MDCK cysts expressing GFP-PRL-3 (C104S catalytically inactive substitution mutant 
(c,e) or wild-type PRL-3, WT (d,f); both green) were grown for 3 days (c,d) or 7 days 
(e,f) and stained as in a and b. Arrows indicate intracellular lumens (d,f). (g) 
Proportion of cysts with a single lumen in MDCK cysts stably expressing GFP-PRL-3 
WT or GFP-PRL-3 C104S. Values represent the means plus standard deviation of 
three experiments. GFP-PRL-3 WT n=158, GFP-PRL-3 C104S n=103. Scale bars 10 
µm.
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Figure IV.2. PRL-3 overexpressing cysts show fully specified lumens in ectopic 
positions. (a-b) Representative images of cysts either expressing GFP-PRL-3 WT (b) 
or expressing the catalytically inactive mutant GFP-PRL-3 C104S (a) (both green) 
incubated with Hoechst (blue) and with antibodies against ZO-1 (red) at 96 h after 
plating. (c-d) Experiments performed as in a and b except cysts were analyzed 48 h 
after seeding and cells were incubated with antibodies against Par3 (red). Bottom: 
higher magnification images of the indicated regions showing GFP-PRL-3 (C104S in 
c and WT in d; left), Par3 (middle) and a merge of these two images (right). (e-f) 
Experiments performed as in c and d except cysts were stained with an antibody 
against threonine-phosphorylated ERM (ezrin/radixin/moesin) proteins (pEzrin) 
shown in red, further details about the antibody are described in the methods section. 
Bottom: separate fluorescent channels showing localization of individual proteins, 
GFP-PRL-3 (C104S in e and WT in f; left) and pEzrin (right). Scale bars 10 µm.
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IV.3.3. PRL-3-induced ectopic lumens arise from incorrectly localized and PRL-
3 enriched apical membrane initiation sites 
The process of polarization in MDCK cysts begins soon after the first cell division 
when apical polarity and trafficking proteins, such as Par3 and Sec8 (also known as 
EXOC4), are delivered to a specialized zone of cell-cell contact, the AMIS5,17 (see 
also Fig. IV.3b and Fig. IV.3d). AMIS specification is one of the earliest steps in 
lumenogenesis and precedes the formation of a tight junction-delimited lumen5,6. To 
gain further insight into the defect in cystogenesis of PRL-3 overexpressing cells, we 
analyzed the process of ectopic lumen formation by live cell imaging. Figure IV.3a 
shows that ectopic lumens arise from intracellular PRL-3-rich patch-like structures 
(Fig. IV.3a arrow and movie1). Furthermore, PRL-3-induced intracellular lumens are 
not stable but seem to be dynamically opened and absorbed during time (Fig. IV.3a 
and Movie1). These PRL-3 intracellular patches stain positive for the AMIS markers 
Par3 (Fig. IV.3c) and Sec8 (Fig. IV.3e, see below). In addition, in PRL-3 WT cysts 
the normal staining of the AMIS at cell-cell contacts in the center of the cysts is lost 
(Fig. IV.3c, IV.3e). The PRL-3-rich patch-like structures are PI(4,5)P2 positive 
intracellular membrane compartments (Fig. IV.S2a) and are surrounded by 
phosphorylated Ezrin (Fig. IV.S2c), which is only found in the central AMIS in 
normal PRL-3 C104S cysts (Fig. IV.S2b).  
In MDCK cysts the delivery of apical determinants to the AMIS requires polarized 
vesicular trafficking, a process that is dependent on the exocyst complex5. Sec8 is a 
key component of the exocyst complex and is one of the first detectable proteins that 
shows an asymmetric distribution, concentrating to the AMIS together with Par35. 
Considering that Sec8 surrounds these PRL-3-rich patch-like structures (Fig. IV.3e) 
we tested the hypothesis that PRL-3 overexpression could redirect vesicle trafficking 
to PRL-3 induced ectopic lumens rather than to the cysts core where the central lumen 
would normally open. Figure IV.3f shows that exocytic vesicles, labeled with 
BODIPY-Tr-Ceramide18, are indeed delivered to nascent PRL-3- induced intracellular 
lumens (see also movie 2). Taken together, these results indicate that PRL-3-induced 
ectopic lumens arise from fully specified apical membrane initiation sites. However, 
these AMIS appear to be incorrectly localized and PRL-3 enriched. 
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Figure IV.3. PRL-3 overexpressing cysts form incorrectly localized and PRL-3 
enriched apical membrane initiation sites. (a) Selected time points of time-lapse live-
cell imaging of a 45 h GFP-PRL-3 WT cyst. Arrow indicates PRL-3 accumulation in 
an intracellular patch that gives rise to an intracellular lumen, which is subsequently 
reabsorbed. (b-e) Representative images of cysts at 45 h stably expressing either 
PRL-3 WT (c, e) or PRL-3 C104S (b, d) treated with Hoechst (blue) and antibodies 
against Par3 (b, c) or Sec8 (d, e) shown in red. PRL-3 WT intracellular patches are 
Par3 positive (c) and surrounded by Sec8 (e). Bottom, higher magnification images of 
the indicated regions showing GFP-PRL-3 (left), Par3 or Sec8 (middle) and a merge 
of these two images (right). Arrowhead in e indicates an additional PRL-3 patch 
surrounded by Sec8. (f) Selected pictures of time-lapse live-cell imaging of 48 h GFP-
PRL-3 WT cysts showing vesicles trafficking to ectopic AMIS. Cysts were pretreated 
with the red-fluorescent BODIPY-TR ceramide (5µM final concentration) at 4 C° for 
30 minutes. Cells were let to recover at 37 C° for 20 minutes before starting the 
image acquisition. Scale bars 10 µm. 
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IV.3.4. PRL-3 interacts with polarity and trafficking proteins  
The above data suggest that PRL-3 could associate with Par3 and Sec8. To address 
this hypothesis, GFP-PRL-3, transiently expressed in HEK293 cells, was 
immunoprecipitated. All three isoforms of endogenous Par3 (Fig. IV.4a) and also 
endogenous Sec8 (Fig. IV.4d) specifically and reproducibly co-precipitated with 
GFP-PRL-3. Reciprocal co-immunoprecipitation experiments further validated these 
interactions (Fig. IV.S3). GFP-PRL-3 C104S was also able to interact with 
endogenous Sec8 (Fig. IV.4d). Since the catalytically inactive mutant of PRL-3 does 
not affect the normal cyst phenotype when overexpressed in MDCK cysts, we can 
exclude that the PRL-3 induced multi-lumen phenotype is simply due to trapping of 
critical lumen determinants such as Sec8 in ectopic positions.  
To test whether PRL-3 binds directly to Par3, recombinant purified PRL-3 was 
incubated with GST-protein fusions of Par3 fragments (Fig. IV.4b). PRL-3 binds 
most strongly to the Par-3 fragment containing the aPKC-binding region (Par3 C) but 
does not detectably bind the N-terminal fragments of Par3 (Fig. IV.4c). 
 Par3 is an evolutionarily conserved cell polarity protein and is part of a ternary 
complex consisting of Par3, Par6 and aPKC19. The interaction between Par3 and 
aPKC is essential for apical membrane formation in MDCK cells, while tight junction 
maturation is not strictly dependent on this interaction15. Since PRL-3 binds Par3 on 
the aPKC-binding region, we investigated if PRL-3 overexpression could interfere 
with Par3-aPKC binding. The results show that the fraction of aPKC bound to Par3 is 
not reduced by PRL-3 overexpression, and we thus conclude that overexpression of 
PRL-3 does not interfere with the formation of the Par3-aPKC complex. Additionally, 
neither the overexpression of PRL-3 C104S nor WT perturbs tight junction de novo 
formation, as measured using a classical calcium switch assay (Fig. IV.S4b,c)20.  
In conclusion, PRL-3 is able to interact with the polarity and trafficking proteins 
Par3 and Sec8. However, it neither interferes with Par3-aPKC interaction nor with the 
tight junction formation pathway. 
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Figure IV.4. PRL-3 interacts with Par3 and Sec8. (a) Endogenous Par3 co-
immunoprecipitated with GFP-PRL-3 in HEK293 cells. Lysates from HEK293 
transfected with GFP control vector or vector encoding GFP-PRL-3 WT were 
immunoprecipitated using GFP-TRAP beads. Immunoprecipitates were 
immunoblotted with antibodies against Par3 (top) and GFP (bottom). (b) Schematic 
diagram showing the domain organizations of Par-3 as well as the various Par-3 
fragments used to construct GST fusion proteins for the pulldown experiments in c. 
(c) PRL-3 directly binds to the C-terminus of Par3 in vitro. GST and GST–Par3 
fragments were used as bait in pulldown experiments adding recombinant PRL-3. 
PRL-3 binding was detected by immunoblot (top). GST fusion proteins were resolved 
by SDS–PAGE and Ponceau S staining (bottom). (d) Endogenous Sec8 co-
immunoprecipitated with GFP-PRL-3 (either WT or C104S mutant) in HEK293 cells. 
Lysates from HEK293 cells transfected with GFP control vector or a plasmid 
encoding GFP PRL-3 WT or C104S were subjected to immunoprecipitation with 
GFP-TRAP beads. Immunoprecipitates were immunoblotted with antibodies against 
Sec8 (top) and GFP (bottom). 
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IV.3.5. Midbody remnants define the apical domain during cyst development  
PRL-3 overexpression led to mislocalization of the AMIS in MDCK cysts. AMIS 
specification is one of the first steps in lumenogenesis in MDCK cysts5,6, but 
currently the signal that specifies the AMIS position is not known. Since polarization 
in MDCK cysts begins immediately after the first cytokinesis17, we hypothesized that 
a remnant of the final stage of cytokinesis (abscission) defines the AMIS position. 
The midbody is the structure that connects the two daughter cells at this stage and that 
is required for their final separation21,22. Recent studies have shown that midbodies 
can persist in post-mitotic cells and participate in functions unrelated with 
cytokinesis13,23–25. To test the idea that midbody remnants could specify the AMIS 
position, we examined midbody marker staining in parental MDCK cysts at different 
stages. At an early stage, when the lumen is still not physically opened, the midbody 
ring markers MKLP1 (also known as KIF23), γ-tubulin and Cep55 stain the center of 
the cysts (Fig. IV.5a,b,c). Interestingly, midbody remnants persist long after lumen 
opening where they can be found to delineate the edge of the lumen (Fig. IV.5d,e,f). 
Staining with Aurora B, an additional midbody marker, further validates these results. 
Aurora B also forms foci in the cyst core at an early stage of cystogenesis (Fig. 
IV.5g,h). However, at later stages, when the lumen is completely opened, Aurora B is 
mainly dispersed in the lumenal space (Fig. IV.5i arrow), in contrast to MKLP1 that 
remains associated with the midbody (Fig. IV.5i arrowhead). This observation can be 
explained by the fact that aged, post-mitotic midbodies can lose some components26. 
In vitro as well in vivo studies in other cell types have shown that after cytokinesis 
midbodies can either be released into the extracellular space or retained by one of the 
daughter cells. Retained midbodies can either be immediately degraded or persist in 
the cytoplasm for extended periods of time13. In MDCK cysts, midbody remnants 
after cytokinesis were still adjacent to the apical membrane through the half-
disassembled intercellular bridge (Fig. IV.5a arrow) and were subsequently released 
into the lumenal space (Fig. IV.5d, see also Fig. IV.6b,c). Taken together, these 
results suggest that midbody remnants could define the AMIS position in MDCK 
cysts and consequently the site of lumen opening. 
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Figure IV.5. Midbody remnants define the lumen position in MDCK cysts. (a-c) 
Representative images of parental MDCK cysts at 45 h after plating (initial stages of 
lumen formation) stained with Hoechst (blue) to visualize nuclei and antibodies 
against midbody remnants proteins (red); MKLP-1 in (a), γ-tubulin in (b) and Cep55 
in (c). Cysts in b were additionally stained with α-tubulin to visualize microtubules 
(green) in order to exclude cytokinesis events. Bottom: higher magnification images 
of the indicated regions showing individual channels (left, middle) and a merge of 
these two images (right). Arrows indicate midbody remnants marking the nascent 
lumen position. (d-f) Experiments performed as in a, b and c except cysts were 
analyzed 72/96 h after seeding (open lumen stage). Arrows in the higher 
magnification images indicate midbody remnants at the edges of the lumen. (g-i) 
AuroraB localization during lumen morphogenesis. Representative parental MDCK 
cysts at different stages during lumen initiation stained with antibody against 
AuroraB (red) and α-tubulin (green) in g and h or MKLP-1 (green) in i. Arrows 
indicate AuroraB localization, arrowhead in i indicate MKLP-1 positive midbody 
remnant. Scale bars 10 µm. 
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IV.3.6. PRL-3 overexpression affects apical lumen formation by altering post-
mitotic midbody fate 
Since PRL-3 overexpression led to the formation of cysts with incorrectly localized 
and frequently intracellular AMISs (Fig. IV.3c,e), we tested the hypothesis that in 
PRL-3 WT cysts the fate of midbody remnants is altered from release into the 
lumenal space to retention. As expected, MKLP1 staining in morphologically normal 
PRL-3 C104S cysts resembled that in parental cysts, with midbody remnants defining 
the AMIS (Fig. IV.6a) and later being adjacent to the lumen (Fig. IV.6b, see also Fig. 
IV.S5h,i,l for additional midbodies staining). Remarkably, in PRL-3 WT 
overexpressing cysts, midbody remnants were mainly retained either on the lateral 
plasma membrane or in the cytoplasm. MKLP1 staining shows that at an early stage 
the midbody remnants are in the PRL-3 intracellular patches we previously 
characterized as mislocalized AMIS (Fig. IV.6d). Moreover, at later cystogenesis 
stages, we found midbody remnants associated with ectopic lumens (Fig. IV.6e). 
Similar results were obtained by co-transfecting mKATE-PRL-3 WT and YFP-
MKLP1 in MDCK cells (Fig. IV.S5a) as well as by staining with additional 
antibodies directed against midbody remnant proteins such as γ−tubulin, Aurora B 
and Cep55 (Fig. IV.S5b,c,d). In agreement with the observations in parental cysts, 
Aurora B was dispersed in the central lumen in PRL-3 C104S normal cysts and also 
in the ectopic lumens that arise in PRL-3 WT cysts (Fig. IV.S5f,i).  
We also analyzed mosaic cysts, which revealed that PRL-3 WT-expressing cells 
extending into the lumenal space have lost midbody remnants. This contrasts with the 
observation made with parental cells in the same mosaic cysts, which maintained 
midbody remnants facing a small lumen. Similarly, in PRL-3 C104S expressing 
mosaic cysts the lumen edge was marked by midbody remnants (Fig. IV.6f,c).  
Next, we carried out live cell imaging experiments using YFP-MKLP1 as a 
midbody remnant marker, to follow the fate of post-mitotic midbody over time in 
morphologically normal PRL-3 C104S cysts and in PRL-3 WT cysts. Figure IV.6g 
shows that at the two-cell stage, normal PRL-3 C104S cysts maintained the post-
mitotic midbody at their center (Fig. IV.6g arrow). Moreover, this first midbody was 
maintained over time and marked the edge of the lumen when it finally opened (Fig. 
IV.6g arrow). The movie also showed that at the following division, the new post-
mitotic midbody was positioned at the apical surface that later delimited, together 
with the older midbody, the nascent lumen (Fig. IV.6g arrowhead). In contrast, 
 78 
midbody remnants in PRL-3 WT cysts followed a different fate and this was 
associated with phenotypic alterations. PRL-3 WT overexpression altered the post-
mitotic midbody fate from release to retention (Fig. IV.6h). Retained post-mitotic 
midbodies either gave rise to ectopic lumens (Fig. IV.6h arrow) or disappeared with 
time (Fig. IV.6h arrowhead).         
In summary, these results show that PRL-3 overexpression in MDCK cysts alters 
post-mitotic midbody fate from release in the luminal space to intracellular or 
intercellular retention. Retained midbodies can either persist or become undetectable, 
possibly through degradation. In the first case ectopic lumens arise at the site where 
the midbodies are retained, in the second case cells appear to lose a fundamental 
polarization signal and extend into the luminal space. 
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Figure IV.6. PRL-3 overexpression induces a multi-lumen phenotype in MDCK 
cysts by altering post-mitotic midbody fate. (a-c) Representative confocal microscopy 
images of cysts expressing GFP-PRL-3 C104S (green) at 45 h (close lumen) or 72 h 
(open lumen and hybrid cysts) after plating and incubated with Hoechst (blue) to 
visualize nuclei and with MKLP-1 antibody (red) to visualize midbody remnants. 
Arrows indicate midbody remnants marking the center of the cysts in a and facing the 
lumen in b and c. Note that in c half of the cells in the cysts are not expressing GFP-
PRL-3 C104S. (d-f) Representative images of cysts expressing GFP-PRL-3 WT at 45 
h (close lumen), 72 h (open lumen) or 5 day (hybrid cysts) after plating stained as 
described in a-c. Arrows indicate cytoplasmic retained midbody remnants marking 
wrong localized AMIS in d and facing an ectopic lumen in e. Note that in f only the 
cells in the cysts that are not expressing PRL-3 WT show midbdody remnants 
(highlighted with arrows) facing the lumen. (g-h) Selected time points of time-lapse 
live-cell imaging of 45 h cysts stably expressing either GFP-PRL-3 C104S (g) or 
GFP-PRL-3 WT (h) transfected with YFP-MKLP-1. Arrow in g highlights the first 
midbody remnant; arrowhead highlights the midbody remnant coming from the 
second cytokinesis. Arrow in h indicates a midbody remnant that gets internalized 
with subsequent ectopic lumen formation; arrowhead highlights a midbody remnant 
that disappears with time. Scale bars 10 µm. 
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IV.4. Discussion 
Understanding how epithelial cells establish and maintain the axis of polarity is a 
fundamental issue for our comprehension of how epithelial tissue organize themselves 
into tubes and cysts. In the present study, we have demonstrated that in MDCK cysts 
the midbody remnant of the first cellular division is the earliest polarization signal 
(Model in Fig. IV.7a). The position of the first post-mitotic midbody defines the 
location of lumen formation and establishes the axis of polarity, converting the 
membrane where it is positioned into the AMIS. Moreover, midbody remnants are 
also maintained in the following division, marking the edge of the lumen when it 
physically opens. It has been shown that the resolution of the membrane connection 
between two daughter cells, during abscission, requires targeting and fusion of 
exocyst vesicles with the intracellular-bridge plasma membrane27. Several subunits of 
the exocyst complex, including Sec8, localized to the midbody ring during abscission 
and formed a ring-like structure27. Thus, the selective localization of key tethering 
factors (such as Sec8) of the exocyst complex at the midbody during abscission could 
be the link between midbody remnant and AMIS specification via polarized 
exocytosis.  
We provide evidence for this model by showing that a perturbation of midbody 
remnant fate is associated with major defects in MDCK cyst morphogenesis. The 
overexpression of the phosphatase PRL-3 alters the fate of the post-mitotic midbody 
from release into the lumenal space to cytoplasmic or lateral plasma membrane 
retention (Model in Fig. IV.7b). The site where the midbody remnant is retained 
became first an ectopic AMIS, enriched in Par3 and surrounded by Sec8, and later on 
an ectopic lumen that stained positive for all the classical luminal markers (Model in 
Fig. IV.7b). Together, our results show that midbody remnants themselves are a 
signal sufficient to drive the entire pathway of de novo lumen formation, leading to 
the opening of completely specified lumens, independently of the position where they 
are located.  
Recently, it has been suggested that midbody remnants could participate in non-
cytokinetic functions, such as cell fate determination and cell polarity 
specification13,23,25. In particular, it has been shown that cytokinesis remnants are the 
earliest landmarks of neuronal polarity in Drosophila melanogaster in vivo24. 
Moreover, in Drosophila follicular epithelium, apical midbody localization provides a 
positional cue critical for the formation of the apico-basal axis of the tissue, as 
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confirmed by disruption of the epithelial architecture in case of midbody ectopic 
localization25. Our results strongly support a function of midbody remnants in 
polarization, showing that during cystogenesis, midbody remnants are the earliest 
signal of polarization. Interestingly, a link between cytokinesis and polarization has 
been also described in unicellular organisms, such as budding yeast, where the post-
mitotic bud scar contributes to cell polarity and to establishing the division axis for 
the next cell division28.  
 
 
Figure IV.7. Midbody remnants are the earliest signal of polarization, determining 
intrinsically the lumen position. (a) Schematic representation of different stages of 
lumenogenesis in MDCK cysts. During the first cytokinesis, members of the exocysts 
complex are delivered to the midbody to complete the abscission. Midbody remnants 
define the AMIS (apical membrane initiation site) that is established by polarized 
exocytosis. Expansion then allows opening of the luminal space, midbody remnants 
mark the edge of the lumen. (b) PRL-3 overexpression affects lumenogenesis by 
altering post-mitotic midbody fate. After the first cytokinesis the post-mitotic midbody 
is internalized and retained in the cytoplasm. This site becomes a wrongly localized 
and PRL-3 enriched AMIS where apical determinants are delivered by exocytosis. 
Expansion then allows opening of ectopic lumens in the position where the midbody 
remnant is retained. Red lines, microtubules; yellow circles, midbody and midbody 
remnants; small red circles, exocysts subunits; blue ovals, nuclei; empty red circles, 
exocysts vescicles. 
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Molecular details of how the fate of midbody remnants is determined will be 
illuminated by the identification of the PRL-3 substrate in this process, which could 
be a key player in the establishment the lumen. Thus far, several protein substrates 
and a non-protein substrate have been suggested, but none has been confirmed yet as 
the substrate that accounts for the pleiotropic effects on cellular signaling caused by 
PRL-3 overexpression12. Indeed, the identification of PRL-3 substrates has remained 
extremely challenging since its discovery over a decade ago11,12. In the context of 
lumen formation, the suggested PRL-3 substrates PI(4,5)P2 and Ezrin are particularly 
attractive candidates as they are known determinants of cellular polarity16. We did not 
observe significant changes in the phosphorylation status of either one of these 
proposed substrates with the methods applied here. Rapid changes of tightly 
controlled phosphorylation levels may however be difficult to detect, and it will take 
the development of elaborate, sensitive methods such as phosphoproteomics at 
distinct time points in 3D cell culture to make progress in this area. Acute changes, 
for example in the concentration of PI(4,5)P2 at relevant locations as seen in other 
processes such as endocytosis and exocytosis29, could account for the alteration of 
midbody fate with its dramatic phenotypic consequences. Alternatively, hitherto 
unknown effects caused by protein-protein interactions that depend on the intact WT 
phosphatase (as opposed to the C104S mutant, which seems to be structurally less 
stable30) could be the critical factor in altering midbody fate. 
The question of whether PRL-3 is a bona-fide oncogene has not yet been addressed 
in detail. In a recent report31, the authors observed elevated expression of PRL-3 in 
the colon of WT mice immediately following the treatment with a carcinogen. In 
addition, WT mice expressed PRL-3 at an elevated level in primary tumors and PRL-
3 knock out mice developed 50% fewer tumors following treatment with 
carcinogens31. These findings suggest strongly that PRL-3 could play a role in colon 
tumorigenesis, aside from its known role in the progression of late stage cancer and 
metastasis11,12. Our data strongly support these findings in that the simple over-
expression of PRL-3 in a non-cancerous background causes detrimental 
disorganization of epithelial structures. Moreover, it is known that one of the earliest 
events following the acquisition of oncogenic mutations by an epithelial cell is the 
formation of multilayered and disorganized structures8. This resembles the phenotype 
exhibited by PRL-3 overexpressing multilayered cells that grow into the cyst lumen in 
a disorganized way.  In addition to the disruption of cell-cell contacts, cell-matrix 
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adhesion and spindle orientation8, switching the fate of midbody remnants could 
therefore be another reason for loss of epithelial organization in cancer. 
We identified midbody remnants as the earliest signal of polarization in 
cystogenesis, and that PRL-3 overexpression alters the fate of the midbody remnants. 
These findings not only offer an explanation for the long unanswered question of how 
the position of the AMIS is specified, but also suggest a novel mechanism for the loss 
of epithelial organization in cancer, including the identification of PRL-3 as an 
enzyme involved in this mechanism. Studying these mechanisms in vivo in epithelial 
organ formation and cancers originating from epithelial tissues will be major 
challenges in developmental and cancer cell biology in the future. 
 
IV.5. Methods 
IV.5.1. Cells 
MDCK cells were grown in Minimum Essential Medium (MEM) containing 10% 
fetal bovine serum (FBS), (both from Gibco, Life Technologies), 100 U/ml penicillin 
and 100 µg/mL streptomycin (Sigma) and 2 mM L-glutamine (Sigma). MDCK stably 
expressing GFP-PRL-3 WT and GFP-PRL-3 C104S were made by transfection 
(Lipofectamine LTX, Life Technologies) of pEGFP-C1-PRL-3 WT and pEGFP-C1-
PRL-3 C104S respectively, and selection with 4mg/ml of Geneticin (Gibco, Life 
Technologies) for 2 weeks. MDCK cells stably co-expressing GFP-PH PLCδ and 
mKATE-PRL-3 (either WT or C104S) were generated by transfection of MDCK 
GFP-PH-PLCδ (provided by F.M. Belmonte, CBMSO, Spain) with pmKATE2-C 
PRL-3 (WT or C104S) and double selection with 4mg/ml of Geneticin and 5 µg/ml of 
Blasticidin S (Invitrogen) for 2 weeks. Transfected cells underwent fluorescence 
activated cell sorting (FACS) after selection. HEK 293 kidney epithelial cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% 
(v/v) FBS, 100 U/ml penicillin and 100 µg/mL streptomycin and 2 mM L-glutamine. 
 
IV.5.2. 3D culture  
MDCK cell cyst formation was performed as described previously16. Briefly, to 
prepare cysts in Matrigel (BD Bioscience) cells were trypsinized to a single cell 
suspension of 4x104 cells/ml in complete medium containing 2% Matrigel. 
Suspensions (250µl) were plated into 8-well coverglass chambers (Nunc), pre-coated 
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with Matrigel diluted 1:10 (v/v) in MEM serum free. Cells were grown for the 
indicated times before fixation in 4% paraformaldehyde (PFA) or for live cell 
imaging experiments. For Annexin‐A2‐mRFP and YFP-MKLP1 expression, cells in 
2D were transiently transfected (Lipofectamine LTX, Life Technologies) before 
plating into 3D.  
 
IV.5.3. Plasmids 
Vectors pEGFP-C1, pmKATE2-C, pCMV-3-FLAG were used to overexpress WT 
human PRL-3. PRL-3 C104S mutant was generated by site-directed mutagenesis30. 
Annexin‐A2‐mRFP construct in clontech N1 vector was obtained from Dr. Carsten 
Schultz (EMBL, Heidelberg). pEGFP-C1 Par3 and pdEYFP-Sec832 were obtained 
from Dr. Rainer Pepperkok (EMBL, Heidelberg). Par3 fragments (Par3A, Par3B, 
Par3C, Par3D) tagged with GST were generated by PCR amplification and cloned 
into pGEX-6P-2rbs vector. In detail, Par3A residues 1-373, Par3B residues 228-704, 
Par3C residues 678-935, Par3D residues 931-1337.  
 
IV.5.4. Antibodies and immunolabelling 
Primary mouse antibodies used were: anti-Sec8 (Immunofluorescence, 1:100; Enzo 
Life Sciences; western blot, 1:300; Santa Cruz Biotechnology); anti-ZO-1-Alexa 
Fluor 594 (1:50; Invitrogen); anti-FLAG M2 (1:1000; Sigma); anti-GFP (1:1000; 
Roche); anti-AuroraB (1:200; BD Transduction Laboratories clone 6/AIM-1); anti-
gamma-tubulin (1:100; Sigma, clone GTU-88); anti-Cep55 (1:100; Abnova). Primary 
rabbit antibodies used were: anti-MKLP1 (1:1000; Santa Cruz Biotechnology); anti-
Par3 (Immunofluorescence, 1:100, western blot, 1:1000; Millipore); anti-alpha-
tubulin (1:500; Millipore, clone EP1332Y); anti-phospho-ERM detecting 
phosphorylation of Ezrin (Thr-567)/Radixin (Thr-564)/Moesin (Thr-558) (1:100; Cell 
signaling Technology), in the experiments was used to detect phosphorylated Ezrin 
considering that MDCK cells express mainly Ezrin of ERM family proteins33. 
Primary sheep antibody used was: anti PKC iota/lambda/zeta (1:000; LifeSpan 
Biosciences). Mouse monoclonal antibody against human PRL-3 (clone 1E7) was 
generated using His-tagged recombinant PRL-3 produced in bacteria and purified 
using nickel resin as immunogen. Specificity of the anti-PRL-3 antibody was 
evaluated by ELISA assays and western immunoblotting using recombinant PRL-1 
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and PRL-3. Alexa fluorophore-conjugated secondary antibodies (1:1000 for all 
secondary antibodies; Invitrogen) or Phalloidin (1:400; Invitrogen) and Hoechst to 
label nuclei (10 mg/ml), were utilized. The procedure for the immunofluorescence 
staining of cysts was previously described in detail34. Briefly, samples were rinsed 
with phosphate-buffered saline (PBS) twice quickly and fixed with 4% PFA for 30 
min. Cells were quenched with 0,1 M glycin in PBS for 20 min, permeabilized with 
0.5% Triton X-100 in PBS for 10 min and blocked with 10% FBS in PBS/0.5% 
Triton for 30 min. Samples were then incubated with primary antibodies in blocking 
solution at 4°C overnight, followed by washing and incubation with Alexa Fluor -
conjugated secondary antibody for 1 hour. To stain Cep55 cells were permeabilized in 
digitonin solution (50mg/ml digitonin in PBS) at 37°C for 5 min, excess of digitonin 
was quenched with 50mM NH4Cl in PBS at 37°C for 5 min, then cells were blocked 
with 2% bovine serum albumin (BSA; Sigma), 5% FBS in PBS at 37°C for 30 min. 
Primary antibody was diluted in blocking solution, cells were incubated for 1 hour at 
37°C.  
 
IV.5.5. Immunoprecipitation and immunoblotting 
Cells were lysed on ice in HNTG (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% 
glycerol, 5 mM EGTA, and 1% Triton X-100) containing complete protease inhibitors 
(Roche). After centrifugation at 12×103×  g for 15  min, the protein concentration was 
measured, and equal amounts of lysate were used for immunoprecipitation. 
Immunoprecipitations were performed with GFP-Trap beads (ChromoTek) overnight 
at 4  °C. Thereafter, the precipitants were washed three times with lysis buffer and the 
immune complexes eluted with sample buffer containing 1% SDS for 5  min at 95  °C. 
The immunoprecipitated proteins were then separated by SDS–PAGE. Western 
blotting was performed with specific antibodies and secondary anti-mouse or anti-
rabbit antibodies conjugated to horseradish peroxidase (Sigma and Amersham 
Biosciences respectively). Visualization was achieved with the Amersham 
Biosciences ECL (Enhanced Chemiluminescence) 
 
IV.5.6. Purification of recombinant proteins and GST-pulldown 
Plasmids expressing GST–Par3 fragments were used to transform the Escherichia coli 
strain BL21. Cultures were grown overnight at 37  °C. The next day, cultures were 
diluted 1:10 in fresh LB medium and grown at 37  °C to an optical density of 0.6 at 
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600  nm. Protein expression was then induced for 3 hours at 37  °C in the presence of 
0.1  mM isopropyl- β-D-thiogalactopyranoside (IPTG). For GST pull-down assays the 
bacteria pellets were resuspended in NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM 
NaCl, 1 mM EDTA, and 0.5% NP-40) supplemented with complete protease 
inhibitors (Roche). After sonication the supernatants of the cell lysates were incubated 
with glutathione magnetic beads (Thermo scientific Pierce) for 1 hour at 4  °C. To test 
direct binding between GST-Par3 fragments and PRL-3, 5mg of GST fusion protein 
bound onto glutathione magnetic beads were incubated for 1 hour at 4  °C in HNTG 
buffer with 100 ng of recombinant PRL-3, purified as described previously30. Beads 
were extensively washed with HNTG, bound protein were eluted with sample buffer 
containing 1% SDS for 5  min at 95  °C and processed for immunoblot analysis. 
 
IV.5.7. Vesicles trafficking 
To label exocysts vesicles cells were treated with 5µM of the red-fluorescent 
BODIPY-TR ceramide complexed to BSA (Invitrogen) at 4 C° for 30 minutes. 
Samples were then rinsed several times with ice-cold medium and incubated in fresh 
medium at 37 C° for further 20 minutes before starting the image acquisition. 
 
IV.5.8. Calcium Switch Assay 
Calcium switch experiments were performed as described previously20. Briefly, 
MDCK cells were plated in eight-well Lab-Tek II chambers with complete growth 
medium (normal calcium medium, HCM). After 24 hr cells were switched into low 
calcium medium (LCM). LCM was prepared by supplementing MEM with 2% FBS 
which was dialysed against 150mM NaCl overnight. After 16 hr incubation in LCM, 
cells were switched back to HCM for the indicated times.  
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IV.7. Supplementary Figures 
 
Figure IV.S1. Ectopic lumens in PRL-3 WT cysts are positive for apical 
determinants. (a-b) Representative images of 72 h cysts either stably expressing the 
catalytically inactive mutant mKATE-PRL-3 C104S (a) or mKATE PRL-3 WT (b) 
(both red) and the PI(4,5)P2 sensor GFP-PH PLCδ (green). Nuclei were stained with 
Hoechst (blue). (c-d) Representative images of 72 h cysts either stably expressing 
GFP-PRL-3 C104S (c) or GFP PRL-3 WT (d) (both green) transiently transfected 
with mRFP-Annexin2 (red). Nuclei were stained with Hoechst (blue). Scale bars 10 
µm.
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Figure IV.S2. PRL-3 intracellular patches are positive for apical determinants. (a) 
Representative images of 45 h cysts stably expressing mKATE PRL-3 WT (red) and 
the PI(4,5)P2 sensor GFP-PH PLCδ (green). Nuclei were stained with Hoechst 
(blue). Arrowhead indicates a PI(4,5)P2 positive PRL-3 patch. (b-c) Representative 
images of cysts either expressing the catalytically inactive mutant GFP-PRL-3 C104S 
(b) or expressing GFP-PRL-3 WT (c) (both green) incubated with Hoechst (blue) and 
with antibodies against threonine-phosphorylated ERM (ezrin/radixin/moesin) 
proteins (pEzrin) shown in red at 45 h after plating. Bottom: higher magnification 
images of the indicated regions showing individual channels (left, middle) and a 
merge of these two images (right). Note in c a PRL-3 patch surrounded by 
phosphorylated Ezrin. Scale bars 10 µm. 
 
 
Figure IV.S3. PRL-3 interacts with Par3 and Sec8. FLAG- tagged PRL-3 co-
immunoprecipitated with GFP-Par3 or GFP-Sec8 in HEK293 cells. Lysates from 
HEK293 co-transfected with FLAG-PRL-3 and GFP control vector or vectors 
encoding either GFP-Par3 or GFP-Sec8 were immunoprecipitated using GFP-TRAP 
beads. Immunoprecipitates were immunoblotted with antibodies against GFP (top) 
and FLAG (bottom). 
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Figure IV.S4. PRL-3 overexpression is interfering neither with Par3-aPKC 
interaction nor with de novo tight junction formation. (a) GFP-Par3 co-
immunoprecipitated endogenous aPKC and also FLAG-PRL-3 in HEK293 cells. 
Lysates from HEK293 transfected with GFP-Par3 or co-transfected with GFP-Par3 
and FLAG-PRL-3 were immunoprecipitated using GFP-TRAP beads. 
Immunoprecipitates were immunoblotted with antibodies against GFP (top), aPKC 
(middle) and FLAG (bottom). In the anti aPKC immunoblot, two bands, 
corresponding to the isoforms PKCζ  and PKCι, can be noted (b-c) PRL-3 
overexpression did not disrupt the relocalization of ZO-1 to cell borders during a 
calcium switch assay. Control GFP-PRL-3 C104S (b) or GFP-PRL-3 WT (c) MDCK 
cells were subjected to a calcium switch. Cells were fixed at the indicated time points 
after restoring normal Ca2+ levels to the growth media and stained with antibodies 
against ZO-1. HCM, normal calcium-containing medium. Scale bars 10 µm. 
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Figure IV.S5. PRL-3 overexpression induces a multi-lumen phenotype in MDCK 
cysts by promoting midbody remnants retention. (a) Representative image of 72 h 
cysts expressing YFP-MKLP-1 and mKATE-PRL-3 WT. Arrow indicate a midbody 
remnant associated with an ectopic lumen. (b-g) Representative confocal microscopy 
images of cysts expressing GFP-PRL-3 WT (green) at 45 h (close lumen) or 72 h 
(open lumen) after plating and incubated with Hoechst (blue) to visualize nuclei and 
with antibodies against midbody remnants proteins (red); γ-tubulin in (b,e), AuroraB 
in (c,f), Cep55 in (d,g). Bottom in (b-d): separate fluorescent channels showing 
localization of individual proteins. Arrows indicate midbody remnants associated 
with PRL-3 intracellular patches previously characterized as ectopic AMIS (b-d) or 
with ectopic lumens (e-f). (h-l) midbody remnants define the central lumen in 
morphologically normal PRL-3 C104S cysts. Representative confocal microscopy 
images of cysts expressing GFP-PRL-3 C104S (green) at 72 h (open lumen) after 
plating and incubated with Hoechst (blue) to visualize nuclei and with antibodies 
against midbody remnants proteins (red); γ-tubulin in (h), AuroraB in (i) Cep55 in 
(l). Arrows indicate midbody remnants marking the central lumen. Scale bars 10 µm. 
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Chapter V: General discussion and perspectives 
 
V.1. Identification of PRL-3 substrates 
PRL-3 belongs to the family of dual specificity phosphatase and its expression 
appears highly restricted and tightly regulated. In agreement with these observations, 
the aberrant expression of PRL-3 is associated with pathological conditions and, in 
particular, correlates with cancer progression, poor prognostic outcome and probably 
with primary tumor development (Rios et al., 2013; Zimmerman et al., 2013). 
Although in the last decade numerous clinical studies have extensively validated the 
role of PRL-3 in cancer, to date its substrate(s) and the direct downstream 
transduction pathways affected by PRL-3 overexpression are still elusive (Bessette et 
al., 2007). The identification of substrates of PRL-3 turned out to be extremely 
challenging, taking into account its extremely low activity in vitro and the tremendous 
pleiotropic effects that its overexpression generates in stable cell lines (Rios et al., 
2013).  
For example, recently a study was published concerning a tyrosine-specific 
phosphoproteomic analysis of squamous epithelial HEK293 cells overexpressing 
PRL-3 (Walls et al., 2013). Phosphoproteomic data revaled a global enhancement in 
tyrosine phosphorylation, similar to the cellular response obtained by transmembrane 
growth factor receptor activation. The authors could not explain the data identifying 
the central “hub” whose phosphorylation was directly affected by PRL-3 
overexpression, but they could only confirm previous observations regarding PRL-3-
dependent Src tyrosine kinase activation. Notably, Src activation itself seems not to 
be directly related with PRL-3 phosphatase activity but is an indirect effect due to 
PRL-3 dependent downregulation of the kinase Csk, a negative regulator of Src 
(Liang et al., 2007). 
On the other hand, also the generation of a PRL-3 knockout mouse has not given 
any clue regarding physiological roles and substrates of PRL-3 (Zimmerman et al., 
2013). Indeed, the lack of a clear phenotype opens the possibility that PRL-3 
physiological functions can be redundant and overcome by other enzymes in vivo. 
Thus, to date, the molecular basis of PRL-3 function remains an enigma. However, 
the identification of PRL-3 substrates is still considered a fundamental goal, not only 
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to provide information about its physiological functions, but also to facilitate the 
development of specific inhibitors possibly useful for clinical purposes.  
Here we show that PRL-3 does not hydrolyze any of a large number of tested 
phosphopeptides. However, we cannot exclude that the phosphatase needs the native 
3D-dimensional structure of the substrates for their recognition or that PRL-3 needs 
co-factors to be fully catalytically competent. On the contrary, we show that PRL-3 
dephosphorylates PtdIns(4,5)P2 in vitro using two distinct biochemical assays. 
Moreover, we provide evidence that PRL-3 could be a 5-phosphatase, hydrolyzing 
PtdIns(4,5)P2 into PtdIns(4)P. 
 Notably, additional members of the class of dual specificity phosphatases are 
primarily lipid phosphatases, namely PTEN and the phosphatases of the myotubularin 
family. These enzymes fulfill their functions by dephosphorylating PtdIns(3,4,5)P3 
and PtdIns(3)P, respectively (Pulido et al., 2013).  
Fluctuations in PtdIns(4,5)P2 levels or its compartmentalization in plasma 
membrane microdomains directly regulate a multitude of cellular responses, including 
exo- and endocytosis, ion channel transport, cytokinesis, cell shape, motility, polarity 
and adhesion (McLaughlin et al., 2002). Thus, PRL-3 activity against PtdIns(4,5)P2 
could partially explain the drastic effects observed when PRL-3 is overexpressed. 
However, to date, we still miss a clear proof that PRL-3 functions as a lipid 
phosphatase activity in cells although several technical approaches, including live cell 
imaging and phosphate radioactive labeling have been attempted (data not shown). 
In addition to the in vitro characterization of PRL-3 phosphatase activity, we have 
also studied the effect of PRL-3 aberrant expression in an organotypic 3D-culture 
system, potentially mimicking the in vivo cancer progression scenario. The results 
show that PRL-3 overexpression, in a 3D model of glandular epithelium, is on its own 
sufficient to perturb dramatically epithelial architecture, with the phosphatase 
behaving as a classical oncogene and consequently reinforcing its pathological 
relevance. From the substrates point of view, we tested in this system two putative 
substrates, Thr567 phosphorylated ezrin and PtdIns(4,5)P2. Unfortunately, we did not 
detect any substantial change in the overall phosphorylation of these two molecules. 
However, we cannot exclude a correlation between the observed phenotype and PRL-
3 lipid phosphatase activity. Indeed, although in PRL-3 overexpressing cysts the 
apical domain is still PtdIns(4,5)P2 enriched, transient and local PtdIns(4,5)P2 
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fluctuations in defined plasma membrane domains could be still behind the 
phenotypic alterations observed.  
Furthermore, we identified the post-mitotic midbody, a remnant organelle from 
cytokinesis, as the first polarization signal during cystogenesis and we prove that 
PRL-3 overexpression disrupts cysts overall epithelial architecture by interfering with 
the fate of post-mitotic midbodies. Three distinct fates of post-mitotic midbodies have 
been described, i.e. their release into the extracellular space or their cytoplasmic 
retention followed or not by degradation through autophagy(Chen et al., 2013). We 
proved that, during cysts development, post-mitotic midbodies are committed to only 
one fate that is apical release, specifying intrinsically the lumen position. Moreover, 
we described that the aberrant expression of PRL-3 alters the fate of post-mitotic 
midbodies by interfering with their release. Finally, we correlate the multi-lumen 
phenotype, observed in PRL-3 overexpressing cysts, with the PRL-3-induced 
alteration of post-mitotic midbodies fate. 
 Recently, multiple lines of evidence have been forwarded to support the notion that 
midbody remnants could participate in functions unrelated to cytokinesis, such as, for 
example, the establishment of neuronal asymmetry (Pollarolo et al., 2011). Moreover, 
it seems that the fate of post-mitotic midbodies could be rigorously cell or tissue-type 
specific. Indeed, it has recently been shown that stem cells are characterized by the 
accumulation of cytoplasmic midbody remnants, a characteristic that is lost when 
stem cells proceed to differentiation (Kuo et al., 2011). In agreement with these 
observations the authors have also shown that the accumulation of aberrant midbody 
remnants through evasion of autophagy is associated with cellular reprogramming and 
an increased tumorigenic potential of selected cell lines. 
 Although several non-cytokinetic roles of midbody remnants have been recently 
described, to date, the signaling pathways governing midbody remnants fate are 
entirely unknown. Thus, to identify and characterize how PRL-3 overexpression alters 
midbody fate determination is extremely challenging.  
At the moment, we are planning to use two distinct strategies to answer this 
question, considering screening-based methods as well as candidate-based 
approaches. In the first case, we are setting the conditions to perform complete 
lipidomic and phosphoproteomic studies of cysts at different stages, in order to 
compare the overall changes induced by PRL-3 overexpression in a 3D model of 
glandular epithelium. In the second case, from a lipid perspective we are planning to 
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investigate a possible role of PtdIns(4,5)P2 immediately after cytokinesis at the 
moment of midbody remnants sorting, whereas from a protein perspective, we are 
mainly focused on GTPases regulating proteins, in particular guanine nucleotide 
exchange factors (GEFs). Indeed, a complex signaling crosstalk between GTPases 
and phosphoinositides at the cleavage furrow during cytokinesis has been recently 
described (Field et al., 2005; Logan and Mandato, 2006).  
It has been suggested that PtdIns(4,5)P2 progressively concentrates at the cleavage 
furrow of dividing cells, facilitating the attachment of the plasma membrane to 
structural components of the actomyosin ring. Interestingly, it seems that during 
furrow progression PtdIns(4,5)P2 levels are not constant but cycle through bursts of 
synthesis and PLC-mediated hydrolysis (Field et al., 2005; Logan and Mandato, 
2006). 
 In addition to PtdIns(4,5)P2, an intriguing hypothesis worthy of further 
investigation is the possible involvement of the GEF Ect2 (epithelial cell transforming 
sequence 2 oncogene) in the PRL-3 mediated phenotype. Ect2 is a component of the 
centralspindlin complex, a multiprotein complex required for the myosin contractile 
ring formation during cytokinesis. It has been reported that Ect2 localizes at the 
midbody during abscission and that the interactions between components of the 
centralspindlin complex, including Ect2, RacGAP and MKLP1, are regulated by 
dynamic events of phosphorylation/dephosphorylation (Saito et al., 2004; Yüce et al., 
2005). Moreover, Ect2 is a Par6/aPKC interacting protein and a direct substrate of 
aPKC (Liu et al., 2006). Although Ect2 knockdown in MDCK cysts is not associated 
with any phenotype, the overexpression of a constitutively active mutant significantly 
affects epithelial morphogenesis, leading to formation of cysts with multiple abnormal 
lumens (Liu et al., 2006; Qin et al., 2010). Ect2 stimulates the activity of members of 
the Rho GTPase family, including RhoA and Cdc42, and most of its biological 
functions described are related to the regulation of cytokinesis (Oceguera-Yanez et 
al., 2005; Yüce et al., 2005). From a pathological perspective, Ect2 is found highly 
overexpressed and mislocalized in several human tumors and its overexpression 
correlates with poor prognosis in patients (Saito et al., 2004). We have identified Ect2 
as a weak PRL-3 interacting protein in a screening for new PRL-3 binding proteins 
(data not shown). We are planning to investigate a possible involvement of Ect2 in 
post-mitotic midbodies fate determination. Indeed, considering the role of this protein 
in cytokinesis as well as its effect on cell polarity, Ect2 is a good candidate-substrate 
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for PRL-3 and could be the direct link between PRL-3 overexpression, alteration of 
the fate of midbody remnants and disruption of epithelial architecture.   
 
V.2. From 3D cell culture models to in vivo studies 
In this work we provide evidence for an important role of post-mitotic midbodies in 
the establishment and maintenance of the axis of polarity and consequently for lumen 
positioning. Moreover, we show that alteration in the position of post-mitotic 
midbodies is associated with ectopic lumen formation whereas their loss, probably by 
degradation, generates a phenotype that resembles luminal filling. Extremely 
attractive is the hypothesis that post-mitotic midbodies could behave as polarity 
landmark in vivo during epithelial tubular organ morphogenesis. Recently, a 
comprehensive study was published on kinesin motor proteins in which the 
localization of the midbody remnant marker MKLP1 has been analyzed in different 
tissues using transgenic mice expressing GFP-labeled MKLP1 (Maliga et al., 2013). 
The figures show multiple midbody remnants facing the luminal space in the 
embryonic neuroepithelium and in the intestinal crypt (Fig. V.1A,B). However, post-
mitotic midbodies were undetectable in other tissues such as liver and kidney (Fig. 
V.1C,D). Moreover the authors did not contextualize the data in reference to epithelial 
cell polarity.  
To confirm if the mechanism of midbody-determined lumen localization is relevant 
during mammalian epithelial tubulogenesis and to test the attractive hypothesis that 
PRL-3 overexpression could drive epithelial tumor formation by altering post-mitotic 
midbodies fate, we are planning to use in vivo and ex vivo mouse-derived models. To 
this end, we are going to generate PRL-3 overexpressing mice, in which the transgene 
expression is under the control of an inducible promoter and can be selectively 
activated in defined epithelial tissues. These experiments will probably answer if 
PRL-3 is a classical oncogene and could reveal a completely new mechanism of 
tumorigenesis based on midbody remnants fate alteration. 
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Figure V.1. Midbody remnants localizazion and tissue distrubution in MKLP1-GFP 
transgenic mice. (A) Confocal image of mouse embryonic neuroepithelium stained 
for DNA (blue) and actin (red). Native GFP-MKLP1 staining (green) shows multiple 
midbody remnants facing the extracellular space (arrows). (B) Section of intestinal 
crypt stained for actin (red) and GFP-MKLP1 (green). (C,D) Tissue sections of liver 
and kidney with artery (A) and glomerulus (G) labeled. MKLP1 staining (green) 
results diffuse with undetectable midbody remnants. Reprinted by permission from 
Macmillan Publishers Ltd: Maliga et al., copyright 2013, Nature Publishing Group. 
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Summary 
Dynamic events of protein and lipid phosphorylation and dephosphorylation are 
involved virtually in all cellular signaling networks and transduction pathways. 
Kinases are the enzymes that catalyze phosphorylation reactions, while phosphatases 
are responsible for phosphate hydrolysis from the substrates. Defective or 
inappropriate activity of phosphatases contributes to the development of many human 
diseases, including cancer. PRL-3 is a plasma membrane-associated dual specificity 
phosphatase that exhibits a highly restricted and tightly regulated expression pattern. 
Additionally, PRL-3 is an emerging prognostic marker for cancer progression and a 
promising therapeutic target. Although in the last decade numerous clinical studies 
have extensively validated the causative role of PRL-3 in cancer metastasis, to date its 
substrate(s) and the direct downstream transduction pathways affected by PRL-3 
overexpression are still elusive. 
The first part of this work concerns the in vitro characterization of PRL-3 
phosphatase activity towards phosphopeptides and phosphoinositides. We show that 
PRL-3 does not present any activity against the library of phosphopeptides tested, 
while it robustly dephosphorylates the phosphoinositide PtdIns(4,5)P2. Moreover, our 
experimental results and molecular docking studies suggest that PRL-3 is a 
phosphatidylinositol 5-phosphatase. Finally, structure-activity relationship studies 
correlate the PRL-3 phosphatase activity toward PI(4,5)P2 with its ability to promote 
cell migration.  
The second part of this work concerns the characterization of PRL-3 oncogenic 
activity with respect to epithelial cell polarity. Using an organotypic 3D-culture 
system, in which epithelial cells form highly organized spherical cysts, we show that 
overexpression of PRL-3 significantly affects epithelial morphogenesis leading to the 
development of cysts with ectopic lumens. Moreover, we prove that a remnant 
organelle from the cytokinesis process, the post-mitotic midbody, is the first 
polarization signal during cyst development. Finally, we show that PRL-3 over-
expression generates major defects in epithelial cell polarization by interfering with 
the fate of post-mitotic midbodies. 
In conclusion, we show that PRL-3 could be a new phosphoinositide phosphatase 
and that its overexpression affects epithelial cell polarization by altering post-mitotic 
midbody fate, suggesting a novel mechanism for epithelial tumorigenesis. 
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Samenvatting 
Dynamische fosforylering en de-fosforylering van eiwitten en vetten liggen ten 
grondslag aan vrijwel alle cellulaire signalerings routes. Kinases zijn de enzymen die 
fosforylering katalyseren, terwijl fosfatases zorg dragen voor de hydrolysering van 
fosfaat-groepen van substraten. Verstoorde activiteit van fosfatases dragen bij aan de 
ontwikkeling van verscheidene ziektes, waaronder kanker. PRL-3 is een bi-specifiek 
fosfatase dat gebonden is aan de cel membraan, en waarvan de expressie strikt 
gereguleerd is. Daarnaast wordt PRL-3 in toenemende mate beschouwd als een 
indicator voor kanker progressie, en daarmee als een veelbelovende target voor 
mogelijke therapie. Hoewel een groot aantal klinische studies gedurende de laatste 10 
jaar het causale verband hebben aangetoond tussen PRL-3 en metastase, is tot op 
heden onbekend welke substraten en signaleringsroutes gereguleerd worden door 
over-expressie van PRL-3.  
Het eerste deel van dit werk betreft de karakterisatie van de enzymatische activiteit 
van PRL-3 ten opzichte van fosfopeptiden en fosfoinositiden. We tonen aan dat PRL-
3 geen activiteit vertoont voor de groep fosfopeptiden die we hebben getest, maar dat 
het zeer actief het fosfoinositide PtdIns(4,5)P2 defosforyleert. Bovendien suggereren 
onze experimenten en docking studies dat PRL-3 een fosfatidylinositol 5-fosfatase is. 
Ten slotte tonen structuur-activiteitsstudies aan dat de fosfatase activiteit van PRL-3 
ten opzichte van PI(4,5)P2 correleert met bevordering van cel migratie. 
Het tweede deel van dit werk betreft de karakterisatie van de oncogene activiteit 
van PRL-3 met betrekking tot polariteit van epitheel cellen. Met behulp van een 
organotypisch 3-dimensionaal cultuur systeem, waarin epitheel cellen zich 
organiseren in bolvormige cysten, tonen we aan dat over-expressie van PRL-3 de 
morfogenese van deze cellen beinvloedt, wat leidt tot de vorming van cysten met een 
ectopisch lumen. Bovendien tonen we aan dat een deel van het orgaan dat onstaat bij 
celdeling, de post-mitotische midbody, het eerste signaal is voor polarisatie gedurende 
ontwikkeling van de cyste. Ten slotte laten we zien dat over-expressie van PRL-3 
leidt tot sterke afwijkingen in polarisatie van epitheel cellen door aan te grijpen op 
post-mitotische midbodies.  
Concluderend hebben we aangetoond dat PRL-3 een nieuw fosfoinositide-fosfatase 
is, en dat de verhoogde concentratie ervan polarisatie van epitheel cellen verstoort 
door mis-localisatie van de midbody. Dit veronderstelt een nieuw mechanisme van 
tumor vorming. 
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